Method for detecting effectiveness of immune strength and medical use of lymphocytes or natural killer cells

By classifying lymphoid cells into subsets and adjusting their percentages to match healthy ranges, the method addresses variability in immune efficacy, improving the effectiveness and safety of immune cell therapies.

JP2024156982AActive Publication Date: 2024-11-06何鈞軒
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2024134699
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-02
Filing Date
2024-08-09
Publication Date
2024-11-06
Estimated Expiration
2043-03-03

AI Technical Summary

Technical Problem

Current methods for evaluating the effectiveness of immune systems in individuals are limited and inconsistent, leading to variability in immune cell therapy outcomes due to differences in immune efficacy between individuals.

Method used

A method involving the classification of lymphoid cells into T cell and natural killer cell subsets based on antigen expression, calculating subset percentages, and comparing them to reference ranges to determine immune effectiveness, followed by cryopreservation and administration of specific subsets to achieve balanced immune efficacy.

Benefits of technology

This approach provides a comprehensive assessment of immune effectiveness, allowing for precise adjustment of immune cell therapies to achieve optimal therapeutic outcomes by ensuring the actual percentages of T cell and natural killer cell subsets align with healthy population ranges, thereby enhancing the efficacy of immune cell therapies and reducing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156982000001_ABST
    Figure 2024156982000001_ABST
Patent Text Reader

Abstract

To provide a method for detecting the effectiveness of immune strength.SOLUTION: A method for detecting the effectiveness of immune strength includes the steps of: calculating a percentage of the number of T cell subsets among lymphoid cells and a percentage of the number of natural killer cell subsets among the lymphoid cells and obtaining an actual percentage of the plurality of T cell subsets and an actual percentage of the plurality of natural killer cell subsets; and determining whether the effectiveness of immune strength is normal based on the actual percentage of the T cell subsets and the actual percentage of the natural killer cell subsets. A more comprehensive inspection of all aspects of functions of an immune system is provided by providing the method for detecting the effectiveness of immune strength. Some embodiments of contents of the present disclosure further provide a plurality of uses of lymphocytes in the preparation of a pharmaceutical composition for the treatment of cancer in an individual. Controlling the actual total number of T cells or the actual total number of natural killer cells within a theoretical range improves the therapeutic effect of cancer.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a method and system for detecting the effectiveness of immunity, and the use of lymphocytes or natural killer cells for preparing a pharmaceutical composition for treating cancer in an individual. [Background technology]

[0002] Human blood accounts for about 1 / 13 of body weight (i.e., a 65 kg body has about 5 liters of blood, with lymphocytes accounting for about 3.5 to 10 billion / liter). Different lymphocyte cells have different activities and functions, and work together to resist foreign pathogens or internal lesions (e.g., cancer) and maintain physiological balance in the body. However, traditional analytical indicators to evaluate the effectiveness of immunity are limited and difficult to comprehensively indicate the state of the immune system.

[0003] In addition, currently, in clinical practice, the choice of cell number in immune cell therapy is generally determined by the doctor's experience and the type of cell. However, due to the large difference in immune efficacy between different human bodies, the efficacy of immune cell therapy varies greatly, which is also a bottleneck in the application of existing immune cell therapy in clinical treatment. Summary of the Invention [Problem to be solved by the invention]

[0004] Therefore, it is a problem to be solved to provide a more complete method for detecting the effectiveness of immunity, and to control the immunity of different human individuals to the same degree before immunotherapy. [Means for solving the problem]

[0005] In some embodiments of the present disclosure, the method includes the steps of providing an in vitro sample of an individual comprising a plurality of lymphocyte cells, including a plurality of T cells and a plurality of natural killer cells; classifying the T cells into a plurality of T cell subsets according to the presence or absence of expression of a plurality of first antigens, including CD28; classifying the natural killer cells into a plurality of natural killer cell subsets according to the presence or absence of expression of a plurality of second antigens, including CD16; calculating the percentage of the number of each of the T cell subsets in the lymphocyte cells and the percentage of the number of each of the natural killer cell subsets in the lymphocyte cells to determine the actual percentage of the plurality of T cell subsets and the plurality of natural killer cell subsets. and determining whether the actual percentages of each T cell subset meet the reference range for the T cell subset, determining whether the actual percentages of each natural killer cell subset meet the reference range for the natural killer cell subset, and determining that the individual's immune efficacy is normal if the actual percentages of each T cell subset of all of said T cell subsets meet the reference range for the T cell subset and if the actual percentages of each natural killer cell subset of all of said natural killer cell subsets meet the reference range for the natural killer cell subset.

[0006] In some embodiments, the T cell subsets include early helper T cells, senescent helper T cells, regulatory helper T cells, early killer T cells, senescent killer T cells, or a combination thereof, where the early helper T cells are CD3+, CD4+, CD45RA+, CD62L+, and CD28+, the senescent helper T cells are CD3+, CD4+, CD45RO+, and CD62L+, the regulatory helper T cells are CD3+, CD4+, CD25+, FoxP3+, and CD39+, the early killer T cells are CD8+, CD27+, CD45RA+, CD62L+, and CD127+, and the senescent killer T cells are CD8+, CD27+, CD45RO+, CD62L+, and CD57+.

[0007] In some embodiments, the reference range for the T cell subsets includes a reference range for early helper T cells, the reference range for early helper T cells being between 20% and 100%.

[0008] In some embodiments, the reference range for a T cell subset includes a reference range for regulatory helper T cells, the reference range for regulatory helper T cells being between 1% and 15%.

[0009] In some embodiments, the reference range for the T cell subset includes a reference range for early killer T cells, the reference range for early killer T cells being between 15% and 100%.

[0010] In some embodiments, the reference range for the T cell subset includes a reference range for senescent killer T cells, the reference range for senescent killer T cells being between 0% and 50%.

[0011] In some embodiments, the reference ranges for T cell subsets are derived from physiological values ​​of a healthy subject population, the healthy subject population being human individuals aged 5 to 85 years who are not affected by immunodeficiency syndromes or immunohypersensitivity syndromes.

[0012] In some embodiments, the method further comprises calculating the percentage of the number of CD28 positive cells in the early helper T cells, the senescent helper T cells and the regulatory helper T cells relative to the sum of the percentages of the number of early helper T cells, the senescent helper T cells and the regulatory helper T cells as 100% to obtain an actual percentage of CD28 positive cells in the helper T cells, and determining whether the actual percentage of CD28 positive cells in the helper T cells meets the reference range for CD28 positive cells in the helper T cells.

[0013] In some embodiments, the reference range for CD28 positivity in helper T cells is 80% to 100%.

[0014] In some embodiments, the reference range of CD28 positivity in helper T cells is derived from physiological values ​​in a healthy subject population, the healthy subject population being human individuals aged 5 to 85 years who are not affected by immunodeficiency syndrome or immunohypersensitivity syndrome.

[0015] In some embodiments, the natural killer cell subsets include killer natural killer cells and regulatory natural killer cells, where the killer natural killer cells are CD16+, CD34+, CD56+, CD94+, and CD117+, and the regulatory natural killer cells are CD34+, CD56+, CD94+, and CD117+.

[0016] In some embodiments, the reference range for the natural killer cell subsets includes a reference range for regulatory natural killer cells, the reference range for regulatory natural killer cells being between 0% and 20%.

[0017] In some embodiments, the reference range of regulatory natural killer cells is derived from physiological values ​​in a healthy population, the healthy population being human individuals aged 5 to 85 years who are not affected by immunodeficiency syndromes or immunohypersensitivity syndromes.

[0018] In some embodiments, the method further comprises the steps of measuring an actual value of the natural killer cell killing ability of the natural killer cells by co-culturing the natural killer cells with a plurality of cancer cells at a specific ratio and calculating a percentage of the death number of the cancer cells to obtain an actual value of the natural killer cell killing ability of the natural killer cells; and determining whether the actual value of the natural killer cell killing ability meets a reference range of the natural killer cell killing ability, where when the number ratio is 6.25, the reference range of the natural killer cell killing ability is 0% to 58.8%, when the number ratio is 12.5, the reference range of the natural killer cell killing ability is 1.7% to 88.7%, when the number ratio is 25, the reference range of the natural killer cell killing ability is 17.4% to 100%, and when the number ratio is 50, the reference range of the natural killer cell killing ability is 35.3% to 100%.

[0019] In some embodiments, the method further comprises cryopreserving each T cell subset if the actual percentages of each T cell subset meet the reference range for the T cell subset, and cryopreserving each natural killer cell subset if the actual percentages of each natural killer cell subset meet the reference range for the natural killer cell subset.

[0020] In some embodiments, the step of cryopreserving each T cell subset or cryopreserving each natural killer cell subset comprises a step of selecting the T cell subset or natural killer cell subset by immunobead cell sorting and a step of cryopreserving the T cell subset or natural killer cell subset.

[0021] In some embodiments according to the present disclosure, there is provided a system for detecting efficacy of immunity, comprising a processor and a memory, wherein the memory has a plurality of computer program instructions stored therein, the computer program instructions, when executed by the processor, cause the processor to perform the steps of: accessing in vitro sample data comprising antigen data on the surface of a plurality of sample cells of the individual; generating number data of a plurality of T cell subsets and number data of a plurality of natural killer cell subsets based on the in vitro sample data, using a cell subset database comprising classification information of T cell subsets and classification information of natural killer cell subsets, wherein the classification information of the T cell subsets comprises a classification index according to the presence or absence of expression of a plurality of first antigens comprising CD28, and the classification information of the natural killer cell subset comprises a classification index according to the presence or absence of expression of a plurality of second antigens comprising CD16; and generating efficacy data of immunity based on the number data of the T cell subsets and the number data of the natural killer cell subsets, using an immunity efficacy evaluation database comprising reference range data of a plurality of T cell subsets and reference range data of a plurality of natural killer cell subsets.

[0022] In some embodiments, the first antigen further comprises CD3, CD4, CD8, CD25, CD27, CD39, CD45RO, CD45RA, CD57, CD62L, CD127, FoxP3, or a combination thereof, and the second antigen further comprises CD34, CD56, CD94, CD117, or a combination thereof.

[0023] In some embodiments, the system further includes an output module coupled to the processor for receiving the immunity efficacy data and outputting it as an immunity efficacy report.

[0024] In some embodiments, the immunity efficacy report includes an immunity efficacy field and a plurality of immunity analysis indicator fields.

[0025] Some embodiments of the present disclosure provide use of a plurality of lymphocytes in the preparation of a pharmaceutical composition for treating cancer in an individual, the lymphocytes comprising a plurality of T cells, a plurality of natural killer cells, or a combination thereof, the treatment comprising the steps of: (a) generating a total number deviation value of T cells between the actual total number of T cells and a theoretical range of the total number of T cells, and generating a total number deviation value of natural killer cells between the actual total number of natural killer cells and the theoretical range of the total number of natural killer cells; and (b) administering a pharmaceutical composition comprising the T cells to the individual such that, based on the total number deviation value of T cells, the actual total number of T cells in the individual satisfies the theoretical range of the total number of T cells, and administering a pharmaceutical composition comprising the natural killer cells to the individual such that, based on the total number deviation value of natural killer cells, the actual total number of natural killer cells in the individual satisfies the theoretical range of the total number of natural killer cells.

[0026] In some embodiments, the theoretical range of the total number of T cells and the theoretical range of the total number of natural killer cells are derived from physiological values ​​of a healthy subject population, the healthy subject population being human individuals aged 5 to 85 years who are not affected by immunodeficiency syndrome or immunohypersensitivity syndrome.

[0027] In some embodiments, the theoretical range for the total number of T cells is 700 cells / microliter to 2500 cells / microliter, and the theoretical range for the total number of natural killer cells is 100 cells / microliter to 300 cells / microliter.

[0028] In some embodiments, the treatment includes the steps of: (a) classifying the lymphocyte cells into a plurality of T cell subsets according to the presence or absence of expression of a plurality of first antigens, and classifying the lymphocyte cells into a plurality of natural killer cell subsets according to the presence or absence of expression of a plurality of second antigens; (b) generating T cell subset deviation values ​​between actual percentages of T cell subsets and a theoretical range of T cell subsets, and generating natural killer cell subset deviation values ​​between actual percentages of natural killer cell subsets and a theoretical range of natural killer cell subsets, the actual percentages of T cell subsets being a function of the number of each T cell subset in the lymphocyte cells. and (c) administering to the individual a pharmaceutical composition comprising a T cell subset such that the actual percentages of the T cell subsets of the individual fulfill the theoretical range of T cell subsets based on the deviation values ​​of the T cell subsets, and administering to the individual a pharmaceutical composition comprising a natural killer cell subset such that the actual percentages of the T cell subsets of the individual fulfill the theoretical range of natural killer cell subsets based on the deviation values ​​of the natural killer cell subsets.

[0029] In some embodiments, the theoretical ranges of the T cell subsets and the theoretical ranges of the natural killer cell subsets are derived from physiological values ​​of a healthy subject population, the healthy subject population being human individuals aged 5 to 85 years who are not affected by immunodeficiency syndromes or immunohypersensitivity syndromes.

[0030] In some embodiments, the T cell subsets include early helper T cells, regulatory helper T cells, early killer T cells, or a combination thereof, where early helper T cells are CD3+, CD4+, CD45RA+, CD62L+, and CD28+, regulatory helper T cells are CD3+, CD4+, CD25+, FoxP3+, and CD39+, and early killer T cells are CD8+, CD27+, CD45RA+, CD62L+, and CD127+.

[0031] In some embodiments, the theoretical range of T cell subsets includes a theoretical range of early helper T cells, a theoretical range of regulatory helper T cells, a theoretical range of early killer T cells, or a combination thereof, wherein the theoretical range of early helper T cells is 35%-100%, the theoretical range of regulatory helper T cells is 3%-10%, and the theoretical range of early killer T cells is 20%-100%.

[0032] In some embodiments, the natural killer cell subsets comprise regulatory natural killer cells, which are CD34+, CD56+, CD94+, and CD117+.

[0033] In some embodiments, the theoretical range of natural killer cell subsets includes a theoretical range of regulatory natural killer cells that is 0% to 10%.

[0034] In some embodiments, the treatment comprises the steps of: (a) classifying the lymphocyte cells into a plurality of T cell subsets according to the presence or absence of expression of a plurality of first antigens, the T cell subsets comprising a first T cell subset and a second T cell subset; (b) generating a deviation value of the T cell subset proportion between an actual value of the two T cell subset proportions and a theoretical range of the two T cell subset proportions, the actual value of the two T cell subset proportions being a number ratio between the first T cell subset and the second T cell subset; and (c) administering to the individual the pharmaceutical composition comprising the first T cell subset or the second T cell subset based on the deviation value of the T cell subset proportions such that the actual value of the individual's two T cell subset proportions satisfies the theoretical range of the two T cell subset proportions.

[0035] In some embodiments, the theoretical ranges of the proportions of the two T cell subsets are derived from physiological values ​​of a healthy subject population, which is comprised of human individuals aged 5 to 85 years who are not affected by immunodeficiency syndrome or immunohypersensitivity syndrome.

[0036] In some embodiments, when the first T cell subset is CD4 positive T cells and the second T cell subset is CD8 positive T cells, the theoretical range of the ratio of the two T cell subsets is 1:1 to 5:1.

[0037] In some embodiments, the treatment further comprises administering immune cell therapy to the individual after administering to the individual a pharmaceutical composition comprising said T cells or a pharmaceutical composition comprising said natural killer cells to the individual.

[0038] In some embodiments, the immune cell therapy comprises natural killer cell therapy, cytokine-induced killer cell immunotherapy, γδ T cell therapy, dendritic cell therapy, tumor infiltrating lymphocyte therapy, chimeric antigen receptor T cell therapy, or a combination thereof.

[0039] In some embodiments, the lymphocytes are derived from an individual and are obtained by in vitro culture.

[0040] In some embodiments, the cancer comprises colorectal cancer, ovarian cancer, prostate cancer, breast cancer, brain cancer, cervical cancer, bladder cancer, anal cancer, uterine cancer, colon cancer, liver cancer, pancreatic cancer, lung cancer, endometrial cancer, bone cancer, testicular cancer, skin cancer, kidney cancer, stomach cancer, esophageal cancer, head and neck cancer, salivary gland cancer, hepatocellular carcinoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, basal cell carcinoma, squamous cell carcinoma of the skin, bile duct carcinoma, Merkel cell carcinoma, or a combination thereof.

[0041] Some embodiments of the present disclosure provide a use of a plurality of natural killer cells for preparing a pharmaceutical composition for treating cancer in an individual, the treatment comprising: (a) measuring an actual value of the killing ability of the natural killer cells, obtained by co-culturing the natural killer cells with a plurality of cancer cells in a certain numerical ratio and generating a percentage of the death number of the cancer cells to obtain an actual value of the killing ability of the natural killer cells; (b) generating a deviation value of the killing ability of the natural killer cells between the actual value of the killing ability of the natural killer cells and the theoretical range of the killing ability of the natural killer cells based on the actual value of the killing ability of the natural killer cells and the theoretical range of the killing ability of the natural killer cells; and (c) administering a pharmaceutical composition comprising the natural killer cells to an individual so that the actual value of the killing ability of the individual's natural killer cells satisfies the theoretical range of the killing ability of the natural killer cells based on the deviation value of the killing ability of the natural killer cells.

[0042] In some embodiments, when the number ratio is 6.25, the theoretical range of the killing ability of natural killer cells is 0% to 58.8%, when the number ratio is 12.5, the theoretical range of the killing ability of natural killer cells is 1.7% to 88.7%, when the number ratio is 25, the theoretical range of the killing ability of natural killer cells is 17.4% to 100%, and when the number ratio is 50, the theoretical range of the killing ability of natural killer cells is 35.3% to 100%.

[0043] In some embodiments, in step (a), when leukocyte interleukin 2 having a number ratio of 50 and an effective concentration of 100 international units / milliliter is added simultaneously to co-culture with the natural killer cells and the cancer cells, the theoretical range of the killing ability of the natural killer cells is 57.4% to 100%.

[0044] In some embodiments, the treatment includes the steps of generating a natural killer cell total number deviation value between the actual total number of natural killer cells and the theoretical range of the total number of natural killer cells, and administering to the individual a pharmaceutical composition comprising natural killer cells based on the deviation value of the killing ability of natural killer cells and the deviation value of the total number of natural killer cells, so that the actual total number of the individual's natural killer cells satisfies the theoretical range of the total number of natural killer cells, thereby causing the actual value of the killing ability of the individual's natural killer cells to satisfy the theoretical range of the killing ability of natural killer cells.

[0045] In some embodiments, the treatment further comprises the steps of: classifying the natural killer cells into a plurality of natural killer cell subsets according to the presence or absence of expression of a plurality of specific antigens, the natural killer cell subsets including regulatory natural killer cells, the regulatory natural killer cells being CD34+, CD56+, CD94+, and CD117+; generating a deviation value of regulatory natural killer cells between an actual percentage of regulatory natural killer cells and a theoretical range of regulatory natural killer cells, the actual percentage of regulatory natural killer cells being a percentage of the number of regulatory natural killer cells in lymphocytes; and administering to the individual a pharmaceutical composition comprising the regulatory natural killer cells, based on the deviation value of the killing ability of natural killer cells and the deviation value of regulatory natural killer cells, so that the actual percentage of the individual's regulatory natural killer cells satisfies the theoretical range of the killing ability of regulatory natural killer cells. [Brief description of the drawings]

[0046] The following description of the drawings is intended to make the above and other objects, features, advantages and embodiments of the present invention more comprehensible. [Figure 1] 1 is a flow chart of a method for detecting the effectiveness of immunity in some embodiments of the present disclosure. [Diagram 2] 1 is a flow chart of steps performed by a processor of the immune efficacy detection system in some embodiments of the present disclosure. [Diagram 3] FIG. 1 is a schematic diagram of an immune efficacy detection system according to some embodiments of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0047] In order to complete the description of the present invention in detail, the following detailed description will be given of the embodiments and specific examples of the present invention, but they are not the only ways to implement or apply the specific examples of the present invention. Each of the examples disclosed below can be combined or substituted when beneficial, and one example can be added to another without the need for further description or explanation. In the following description, numerous specific details are described to enable the reader to fully understand the following examples. However, the embodiments of the present invention may be implemented without the specific details.

[0048] In this context, unless specifically limited, "a" and "the above" generally refer to one or more. As used herein, the terms "comprise," "include," "having," and similar words refer to the stated features, regions, integers, steps, operations, elements, and / or components, but should be understood to not exclude other features, regions, integers, steps, operations, elements, components, and / or groups thereof.

[0049] In this text, the deviation is the difference obtained by subtracting two numbers. For example, the deviation of the total number of T cells between the actual total number of T cells and the theoretical range of the total number of T cells is the difference between the actual total number of T cells minus the theoretical range of the total number of T cells.

[0050] Although the methods disclosed herein are described below using a sequence of operations or steps, the order in which the operations or steps are presented should not be construed as limiting the invention. For example, certain operations or steps may be performed in a different order and / or simultaneously with other steps. It is noted that not all operations, steps and / or features need to be performed to achieve an embodiment of the invention. Moreover, each operation or step described herein may include multiple sub-steps or actions.

[0051] Please refer to Figure 1. A method 100 for detecting the effectiveness of immunity according to some embodiments of the present disclosure includes steps S110 to S140.

[0052] First, step S110 provides an in vitro sample of an individual, the in vitro sample including a plurality of lymphocyte cells, the lymphocyte cells including T cells and natural killer cells.

[0053] In some embodiments, the in vitro sample is human blood.

[0054] Next, step S120 classifies the lymphocyte cells into a plurality of T cell subsets depending on the presence or absence of expression of a plurality of first antigens including CD28, and classifies the lymphocyte cells into a plurality of natural killer cell subsets depending on the presence or absence of expression of a plurality of second antigens including CD16.

[0055] In some embodiments, the first antigen further comprises CD3, CD4, CD8, CD25, CD27, CD39, CD45RO, CD45RA, CD57, CD62L, CD127, FoxP3, or a combination thereof. In some embodiments, the second antigen further comprises CD34, CD56, CD94, CD117, or a combination thereof.

[0056] Furthermore, since CD28 is a surface antigen of early helper cells in the T cell subset and CD16 is a surface antigen of killer natural killer cells, step S120 makes it possible to classify at least the T cell subset into early helper cells and non-early helper cells, and the natural killer cell subset into killer natural killer cells and non-killer natural killer cells.

[0057] In some embodiments, sorting the T cells into a plurality of T cell subsets comprises sorting the T cells into early helper T cells (CD3+CD4+CD45RA+CD62L+CD28+), senescent helper T cells (CD3+CD4+CD45RO+CD62L+), regulatory helper T cells (CD3+CD4+CD25+FoxP3+CD39+), early killer T cells (CD8+CD27+CD45RA+CD62L+CD127+), senescent killer T cells (CD8+CD27+CD45RO+CD62L+CD57+), or a combination thereof.

[0058] In some embodiments, natural killer cell subsets include killer natural killer cells (CD16+CD34+CD56+CD94+CD117+) and regulatory natural killer cells (CD34+CD56+CD94+CD117+).

[0059] Next, step S130 calculates the percentage of the number of each T cell subset in the lymphocyte cells and the percentage of the number of each natural killer cell subset in the lymphocyte cells to obtain an actual percentage of the plurality of T cell subsets and an actual percentage of the plurality of natural killer cell subsets. In some embodiments, the actual percentage of the plurality of T cell subsets includes an actual percentage of early helper T cells, an actual percentage of senescent helper T cells, an actual percentage of regulatory helper T cells, an actual percentage of early killer T cells, an actual percentage of senescent killer T cells, or a combination thereof. In some embodiments, the actual percentage of the plurality of natural killer cell subsets includes an actual percentage of killer natural killer cells, an actual percentage of regulatory natural killer cells, or a combination thereof.

[0060] Next, step S140 determines whether the actual percentage of each T cell subset meets the reference range for each T cell subset, and determines whether the actual percentage of each natural killer cell subset meets the reference range for each natural killer cell subset.

[0061] In some embodiments, the reference ranges for the T cell subsets and the reference ranges for the natural killer cell subsets are derived from physiological values ​​of a healthy population, the healthy population being human individuals aged 5 to 85 years who are free of immune deficiency syndromes (e.g., acquired immune deficiency syndrome) and immune hyperactivity syndromes (e.g., autoimmune diseases).

[0062] In some embodiments, the reference range for each T cell subset or the reference range for each natural killer cell subset includes the corresponding acceptable range and theoretical range, i.e., the reference range for a T cell subset includes the acceptable range for the T cell subset and the theoretical range for the T cell subset, and the reference range for a natural killer cell subset includes the acceptable range for the natural killer cell subset and the theoretical range for the natural killer subset.

[0063] If the actual percentages of all T cell subsets all meet the reference ranges of the corresponding T cell subsets and the actual percentages of all natural killer cell subsets all meet the reference ranges of the corresponding natural killer cell subsets (e.g., the actual percentages of all T cell subsets and the actual percentages of all natural killer cell subsets all meet their respective accepted or theoretical ranges), the immunological efficacy is determined to be normal. In some embodiments, the immunological efficacy is further determined to be good if the actual percentages of all T cell subsets all meet the theoretical ranges of the corresponding T cell subsets and the actual percentages of all natural killer cell subsets all meet the theoretical ranges of the corresponding natural killer cell subsets.

[0064] If the actual percentage of any T cell subset does not meet the reference range for the corresponding T cell subset, or if the actual percentage of the natural killer cell subset does not meet the reference range for the natural killer cell subset, then the efficacy of immunity is determined to be low.

[0065] In some embodiments, the reference range of the T cell subset includes a reference range of early helper T cells, a reference range of regulatory helper T cells, a reference range of early killer T cells, or a reference range of senescent killer T cells. The reference range of early helper T cells is 20%-100%, with 20%≦acceptable range<35%, and a theoretical range of 35%-100%. The reference range of regulatory helper T cells is 1%-15%, with 1%≦acceptable range<3% and 10%<acceptable range≦15%, and a theoretical range of 3%-10%. The reference range of early killer T cells is 15%-100%, with 15%≦acceptable range<20%, and a theoretical range of 20%-100%. The reference range of senescent killer T cells is 0%-50%, with 30%<acceptable range≦50%, and a theoretical range of 0%-30%.

[0066] In some embodiments, the reference ranges for natural killer cell subsets include a reference range for regulatory natural killer cells, the reference range for regulatory natural killer cells being 0%-20%, with 10%<acceptable range≦20%, and a theoretical range being 0%-10%.

[0067] Furthermore, depending on whether the actual percentages of each T cell subset and each natural killer cell subset meet the reference ranges of the corresponding T cell subsets and natural killer cell subsets, the immune system's defense against each disease and the risk of contracting a particular disease are further analyzed.

[0068] For example, the actual percentages of early helper T cells and early killer T cells falling within the respective reference ranges (the reference range of early helper T cells or the reference range of early killer T cells) indicate good protection against new pathogens. The actual percentages of early killer T cells falling within the reference range of early killer T cells indicate good inhibition ability against cancer. The actual percentages of regulatory helper T cells higher than the reference range of regulatory helper T cells excessively inhibit other immune cells, leading to high mortality rates in the case of cancer. The actual percentages of senescent killer T cells higher than the reference range of senescent killer T cells indicate aging or failure of the immune system. The actual percentages of regulatory natural killer cells higher than the reference range of regulatory natural killer cells excessively inhibit the activity of killer natural killer cells, leading to a high probability of an individual being infected with a chronic virus.

[0069] In some embodiments, the method 100 includes steps of calculating the percentage of the number of CD28 positive cells in the initial helper T cells, the senescent helper T cells, and the regulatory helper T cells (the proportion of CD28 positive (CD28+) cells in the helper T cells, i.e., the percentage of the number of initial helper T cells among the helper T cells) relative to the sum of the percentages of the number of senescent helper T cells and regulatory helper T cells being 100%, obtaining an actual percentage of CD28 positive cells in the helper T cells, and determining whether the actual percentage of CD28 positive cells in the helper T cells meets the reference range of CD28 positive cells in the helper T cells, thereby grasping the risk of an individual suffering from an autoimmune disease.

[0070] In some embodiments, the reference range of CD28 positivity in helper T cells is derived from physiological values ​​in a healthy subject population, the healthy subject population being human individuals aged 5 to 85 years who are not affected by immunodeficiency syndrome or immunohypersensitivity syndrome.

[0071] In some embodiments, the reference range of CD28 positivity (CD28+) in helper T cells is greater than 80%-100%, with 80%≦acceptable range<90%, and the theoretical range is 90%-100%. Therefore, if the actual percentage of CD28 positivity (CD28+) in helper T cells is less than 80%, there is a high probability of suffering from an autoimmune disease.

[0072] In some embodiments, method 100 includes the steps of measuring the actual value of the natural killer cell killing ability of natural killer cells (the actual value of the natural killer cell killing ability is calculated by co-culturing the calculated natural killer cells and cancer cells in a specific ratio and calculating the percentage of cancer cell deaths to obtain the actual value of the natural killer cell killing ability) and determining whether the actual value of the natural killer cell killing ability meets a reference range of the natural killer cell killing ability, where if the actual value of the natural killer cell killing ability falls within the reference range of the natural killer cell killing ability, it indicates that the natural killer cell has excellent inhibitory ability against cancer. For example, when the number ratio is 6.25, the reference range of the killing ability of natural killer cells is 0% to 58.8%, when the number ratio is 12.5, the reference range of the killing ability of natural killer cells is 1.7% to 88.7%, when the number ratio is 25, the reference range of the killing ability of natural killer cells is 17.4% to 100%, and when the number ratio is 50, the reference range of the killing ability of natural killer cells is 35.3% to 100%. In some embodiments, the reference range of the killing ability of natural killer cells is derived from the physiological values ​​of a healthy group, which is a human individual aged 5 to 85 years who is not affected by immunodeficiency syndrome and immune hyperactivation syndrome.

[0073] In some embodiments, different ratios of natural killer cells and human immortalized myeloid leukemia cells (K-562 cells) are co-cultured, and the rate at which K-562 cells die is measured to evaluate the killing ability of natural killer cells, and the ratio of IL-2 to K-562 cells may be 6.25, 12.5, 25 or 50.

[0074] Furthermore, by adding leukocyte interleukin 2 (IL-2), the activity of regulatory natural killer cells (which inhibit the activity of killer natural killer cells) is completely inhibited, and the activity of killer natural killer cells is acquired, allowing the maximum activity of natural killer cells to be further analyzed.

[0075] In some embodiments, the method 100 further comprises calculating the T cell and natural killer cell content in the in vitro sample (e.g., how many T cells and natural killer cells are there per milliliter of blood) to analyze the overall status of the immune system. For example, a total natural killer cell count (the number of natural killer cells in a whole blood sample per microliter) of less than 50 (less than 50) indicates a high risk of developing cancer.

[0076] In some embodiments, method 100 further includes the steps of cryopreserving each T cell subset if the actual percentages of each T cell subset meet the reference range for each T cell subset, and cryopreserving each natural killer cell subset if the actual percentages of each natural killer cell subset meet the reference range for each natural killer cell subset.

[0077] In some embodiments, if the actual percentages of the natural killer cell subsets and the actual values ​​of the killing capacity of the natural killer cells are both within the corresponding reference ranges, the natural killer cell subsets (e.g., killer natural killer cells and regulatory natural killer cells) are cryopreserved.

[0078] In some embodiments, a T cell subset or a natural killer cell subset (e.g., a T cell subset such as an early helper T cell, an aged helper T cell, a regulatory helper T cell, an early killer T cell, or an aged killer T cell, or a natural killer cell subset such as a killer natural killer cell or a regulatory natural killer cell) can be selected by the immune bead cell sorting method, and the T cell subset or the natural killer cell subset is cryopreserved. Note that conventional methods such as immunoprecipitation and centrifugation are prone to damage cells, and subculture or cryopreservation cannot be sustained. In contrast, cells separated by the immune bead cell sorting method can be made active even after multiple sortings, which is advantageous for amplification and storage.

[0079] In some embodiments, positive sorting systems, negative sorting systems, or combinations thereof can be used to select T cell subsets or natural killer cell subsets. In some embodiments, CD3, CD4, CD8, CD25, CD27, CD28, CD39, CD45, CD45RO, CD45RA, CD57, CD62L, CD127, FoxP3, or combinations thereof can be used to select early helper T cells, senescent helper T cells, regulatory helper T cells, early killer T cells, and senescent killer T cells. In some embodiments, CD16, CD34, CD56, CD94, CD117, or combinations thereof can be used to select killer natural killer cells and regulatory natural killer cells.

[0080] Some embodiments of the present disclosure further provide a detection system for immunity effectiveness, comprising a processor and a memory, wherein a plurality of computer program instructions are stored in the memory, and when the computer program instructions are executed by the processor, the processor performs flow 200 including steps S210 to S230, see FIG. 2.

[0081] First, step S210 accesses in vitro sample data that includes antigen surface data of a plurality of sample cells from an individual. In some embodiments, the sample cell surface antigen data is analyzed by a flow cytometer.

[0082] Next, see step S220. Using a cell subset database, generate number data of a plurality of T cell subsets and number data of a plurality of natural killer cell subsets based on the in vitro sample data. The cell subset database includes classification information of T cell subsets and classification information of natural killer cell subsets, the classification information of T cell subsets includes classification index according to the presence or absence of expression of a plurality of first antigens including CD28, and the classification information of natural killer cell subsets includes classification index according to the presence or absence of expression of a plurality of second antigens including CD16.

[0083] In some embodiments, the first antigen further comprises CD3, CD4, CD8, CD25, CD27, CD39, CD45RO, CD45RA, CD57, CD62L, CD127, FoxP3, or a combination thereof, and the second antigen further comprises CD34, CD56, CD94, CD117, or a combination thereof.

[0084] In some embodiments, the classification information of the T cell subsets includes antigen expression information of each T cell subset, for example, early helper T cells are CD3+CD4+CD45RA+CD62L+CD28+. The classification information of the natural killer cell subsets includes antigen expression information of each natural killer cell subset, for example, regulatory natural killer cells are CD34+CD56+CD94+CD117+.

[0085] In some embodiments, the T cell subset count data and the natural killer cell subset count data comprise the percentage of the number of each T cell subset or each natural killer cell subset in lymphocytes, e.g., the percentage of the number of early helper T cells in lymphocytes.

[0086] Next, see step S230. Using an immunity effectiveness evaluation database, immunity effectiveness data is generated based on the data of the number of T cell subsets and the data of the number of natural killer cell subsets. The immunity effectiveness evaluation database includes reference range data of a plurality of T cell subsets (e.g., including the reference range of the T cell subsets shown in the above method 100) and reference range data of a plurality of natural killer cell subsets (e.g., the reference range of the natural killer cell subsets shown in the above method 100).

[0087] In some embodiments, the system further includes an output module coupled to the processor for receiving the immune efficacy data and outputting it as an immune efficacy report (e.g., displayed on a display screen) to evaluate the immune efficacy of the individual and determine whether to cryopreserve the cells, the immune efficacy report including an immune efficacy field (describing the superior or inferior degree of immune efficacy) and a plurality of immune analysis indicator fields (including the percentage of each cell subset).

[0088] In some embodiments, the reference range data for each T cell subset or the reference range data for each natural killer cell subset includes corresponding acceptable range data and theoretical range data, i.e., the reference range data for the T cell subset includes acceptable range data for the T cell subset and theoretical range data for the T cell subset, and the reference range data for the natural killer cell subset includes acceptable range data for the natural killer cell subset and theoretical range data for the natural killer subset.

[0089] If the number data of all T cell subsets meet the reference range data of the corresponding T cell subsets and the number data of all natural killer cell subsets meet the reference range data of the corresponding natural killer cell subsets (e.g., the number data of all T cell subsets and the number data of all natural killer cell subsets meet their respective acceptable range data or theoretical range data), the immunological efficacy field is written as normal. In some embodiments, if the number data of all T cell subsets meet the theoretical range data of the corresponding T cell subsets and the number data of all natural killer cell subsets meet the theoretical range data of the corresponding natural killer cell subsets, it is further determined that the immunological efficacy is good.

[0090] If the number data for any T cell subset does not meet the reference range data for the corresponding T cell subset, or the number data for any natural killer cell subset does not meet the reference range data for the natural killer cell subset, the effectiveness of immunity is determined to be low.

[0091] In some other embodiments, the reference range data for each T cell subset or the reference range data for each natural killer cell subset is theoretical range data.

[0092] Some embodiments of the present disclosure provide for the use of a plurality of lymphocytes in the preparation of a pharmaceutical composition for treating cancer in an individual, the lymphocytes comprising a plurality of T cells, a plurality of natural killer cells, or a combination thereof, the treatment comprising the steps of (a) generating a total number deviation value of T cells between the actual total number of T cells and the theoretical range of the total number of T cells and a total number deviation value of natural killer cells between the actual total number of natural killer cells and the theoretical range of the total number of natural killer cells, and (b) administering to the individual the pharmaceutical composition comprising the T cells such that the actual total number of T cells of the individual fills the theoretical range of the total number of T cells based on the total number deviation value of T cells, and administering to the individual the pharmaceutical composition comprising natural killer cells such that the actual total number of natural killer cells of the individual fills the theoretical range of the total number of natural killer cells based on the total number deviation value of natural killer cells.

[0093] It is known that individuals suffering from cancer often have poor immune efficacy due to a lack of the actual total number of T cells, the actual total number of natural killer cells, or both. The present disclosure adjusts the efficacy of the individual's immune system to a healthy state by controlling the actual total number of T cells and the actual total number of natural killer cells within a theoretical range, thereby improving the resistance ability of the individual's immune system against cancer and improving the efficacy of cancer treatment. Compared to conventional radiation therapy and chemotherapy, the use of the present disclosure does not damage autologous cells. It should be noted that the use of the present disclosure can be used in conjunction with other immune cell therapies, and by accurately controlling the actual total number of T cells and the actual total number of natural killer cells, the efficacy of immune cell therapy is enhanced and side effects such as overreactions (e.g., cytokine storms) due to estimation errors in the actual total number of T cells or the actual total number of natural killer cells are avoided.

[0094] In some embodiments, the theoretical range of the total number of T cells and the theoretical range of the total number of natural killer cells are derived from physiological values ​​of a healthy subject population, the healthy subject population being human individuals aged 5 to 85 years who are not affected by immunodeficiency syndrome or immunohypersensitivity syndrome.

[0095] In some embodiments, the theoretical range for the total number of T cells is between 700 cells / microliter and 2500 cells / microliter (e.g., 700 cells / microliter, 800 cells / microliter, 900 cells / microliter, 1000 cells / microliter, 1100 cells / microliter, 1200 cells / microliter, 1300 cells / microliter, 1400 cells / microliter, 1500 cells / microliter, 1600 cells / microliter, 1700 cells / microliter, 1800 cells / microliter, 1900 cells / microliter, 2000 cells / microliter, 2100 cells / microliter, 2200 cells / microliter, 2300 cells / microliter, 2400 cells / microliter, 2500 cells / microliter, 2600 cells / microliter, 2700 cells / microliter, 2800 cells / microliter, 2900 cells / microliter, 3000 cells / microliter, 3100 cells / microliter, 3200 cells / microliter, 3300 cells / microliter, 3400 cells / microliter, 3500 cells / microliter, 3600 cells / microliter, 3700 cells / microliter, 3800 cells / microliter, 3900 cells / microliter, 4000 cells / microliter, 4100 cells / microliter, 4200 cells / microliter, 4300 cells / microliter, 4400 cells / microliter, 4500 cells / microliter, 4600 cells / microliter, 4700 cells / microliter, 4800 cells / microliter, 4900 cells / microliter, 5000 cells / microliter, 5100 cells / microliter, 5200 cells / microliter, 5300 cells / microliter, 540 The theoretical range of the total number of natural killer cells is 100 / microliter to 300 / microliter (e.g., 100 / microliter, 200 / microliter, 300 / microliter, or a value between the above ranges). If the actual total number of T cells is smaller than the theoretical range of the total number of T cells, the actual total number of natural killer cells is smaller than the theoretical range of the total number of natural killer cells, or the two conditions exist simultaneously, the immune efficacy of the individual may be reduced. Conversely, if the actual total number of T cells is larger than the theoretical range of the total number of T cells, the actual total number of natural killer cells is larger than the theoretical range of the total number of natural killer cells, or the two conditions exist simultaneously, autoimmunity may become excessive.

[0096] In some embodiments, the T cell count deviation or natural killer cell count deviation is combined with the blood content of the individual (e.g., a 65 kg individual has a blood volume of approximately 5 liters) to generate the appropriate dose at which the T cells or natural killer cells should be administered.

[0097] In some embodiments, the treatment includes the steps of: (a) classifying the lymphocyte cells into a plurality of T cell subsets according to the presence or absence of expression of a plurality of first antigens, and classifying the lymphocyte cells into a plurality of natural killer cell subsets according to the presence or absence of expression of a plurality of second antigens; (b) generating T cell subset deviation values ​​between actual percentages of T cell subsets and a theoretical range of T cell subsets, and generating natural killer cell subset deviation values ​​between actual percentages of natural killer cell subsets and a theoretical range of natural killer cell subsets, the actual percentages of T cell subsets being proportional to the number of each T cell subset in the lymphocyte cells. and the actual percentages of the natural killer cell subsets are percentages of the number of each natural killer cell subset in the lymphocytes; and (c) administering to the individual a pharmaceutical composition comprising the T cell subsets such that the actual percentages of the T cell subsets in the individual fulfill the theoretical range of the T cell subsets based on the deviation values ​​of the T cell subsets, and administering to the individual a pharmaceutical composition comprising the natural killer cell subsets such that the actual percentages of the natural killer cell subsets in the individual fulfill the theoretical range of the natural killer cell subsets based on the deviation values ​​of the natural killer cell subsets.

[0098] Furthermore, a pharmaceutical composition containing a T cell subset or a natural killer cell subset is administered to an individual based on the deviation value of a T cell subset or the deviation value of a natural killer cell subset to adjust the actual total number of T cells or the actual total number of natural killer cells, while further adjusting the T cell subsets and natural killer cell subsets that govern anti-cancer and killing in the immune system, thereby achieving more precise control over immune efficacy.

[0099] In some embodiments, the theoretical ranges of the T cell subsets and the theoretical ranges of the natural killer cell subsets are derived from physiological values ​​of a healthy subject population, the healthy subject population being human individuals aged 5 to 85 years who are not affected by immunodeficiency syndromes or immunohypersensitivity syndromes.

[0100] In some embodiments, depending on the blood content of the individual (e.g., a 65 kg individual has a blood volume of approximately 5 liters), the deviation values ​​of the T cell subsets and the actual total number of T cells or the deviation values ​​of the natural killer cell subsets and the actual total number of natural killer cells are combined to generate the appropriate dosage at which each T cell subset or natural killer subset should be administered.

[0101] In some embodiments, the first antigen comprises CD3, CD4, CD8, CD25, CD27, CD28, CD39, CD45RO, CD45RA, CD57, CD62L, CD127, FoxP3, or a combination thereof. In some embodiments, the second antigen comprises CD16, CD34, CD56, CD94, CD117, or a combination thereof. In some embodiments, sorting the T cells into a plurality of T cell subsets comprises sorting the T cells into early helper T cells (CD3+CD4+CD45RA+CD62L+CD28+), senescent helper T cells (CD3+CD4+CD45RO+CD62L+), regulatory helper T cells (CD3+CD4+CD25+FoxP3+CD39+), early killer T cells (CD8+CD27+CD45RA+CD62L+CD127+), senescent killer T cells (CD8+CD27+CD45RO+CD62L+CD57+), or a combination thereof.

[0102] In some embodiments, natural killer cell subsets include killer natural killer cells (CD16+CD34+CD56+CD94+CD117+) and regulatory natural killer cells (CD34+CD56+CD94+CD117+).

[0103] In some embodiments, the actual percentages of T cell subsets include the actual percentage of early helper T cells, the actual percentage of senescent helper T cells, the actual percentage of regulatory helper T cells, the actual percentage of early killer T cells, the actual percentage of senescent killer T cells, or a combination thereof. In some embodiments, the actual percentages of natural killer cell subsets include the actual percentage of killer natural killer cells, the actual percentage of regulatory natural killer cells, or a combination thereof.

[0104] In some embodiments, the theoretical range of T cell subsets includes a theoretical range of early helper T cells, a theoretical range of regulatory helper T cells, a theoretical range of early killer T cells, or a theoretical range of senescent killer T cells. The theoretical range of early helper T cells is 35%-100%, the theoretical range of regulatory helper T cells is 3%-10%, the theoretical range of early killer T cells is 20%-100%, and the theoretical range of senescent killer T cells is 0%-30%.

[0105] In some embodiments, the theoretical range of natural killer cell subsets includes a theoretical range of regulatory natural killer cells that is 0% to 10%.

[0106] In some embodiments, the early helper T cells and early killer T cells can provide the immune system with protection against cancer cells, so that when the actual percentage of early helper T cells or the actual percentage of early killer T cells is lower than the respective theoretical ranges, the individual's immune system will be less effective at killing cancer cells. By administering the individual's missing early helper T cells or early killer T cells, the individual's immune efficacy can be restored to a healthy state and the immune system's anti-cancer effectiveness can be enhanced.

[0107] In some embodiments, regulatory helper T cells are used to inhibit other lymphocytes (e.g., other T cell subsets) and balance the efficacy of the immune system. Therefore, if the actual percentage of regulatory helper T cells is higher than the theoretical range of regulatory helper T cells, it will excessively inhibit other lymphocytes, reduce immune efficacy, and increase the mortality rate when an individual suffers from cancer. By removing the excess regulatory helper T cells in an individual, the immune efficacy of the individual can be restored to a healthy state and the immune system can be made more effective against cancer.

[0108] In some embodiments, the senescent killer T cells represent the senescent state of the immune system of an individual, so that an actual percentage of the senescent killer T cells higher than the theoretical range of the senescent killer T cells indicates senescence or failure of the immune system. Removal of excess senescent killer T cells in an individual can restore the immune efficacy of the individual to a healthy state and enhance the immune system's anti-cancer efficacy.

[0109] In some embodiments, regulatory natural killer cells are used to inhibit other lymphocytes (e.g., killer natural killer cells) and balance the efficacy of the immune system. Therefore, if the actual percentage of regulatory natural killer cells is higher than the theoretical range of regulatory natural killer cells, it will excessively inhibit other lymphocytes, reduce immune efficacy, and increase the mortality rate when an individual suffers from cancer. By removing the excessive regulatory natural killer cells in an individual, the immune efficacy of the individual can be restored to a healthy state and the immune system's efficacy against cancer can be increased.

[0110] In some embodiments, the treatment includes the steps of: (a) classifying the lymphocyte cells into a plurality of T cell subsets according to the presence or absence of expression of a plurality of first antigens, the T cell subsets including a first T cell subset and a second T cell subset; (b) generating a deviation value of the T cell subset proportion between an actual value of the two T cell subset proportions and a theoretical range of the two T cell subset proportions, the actual value of the two T cell subset proportions being a number ratio between the first T cell subset and the second T cell subset; and (c) administering to the individual a pharmaceutical composition including the first T cell subset or the second T cell subset based on the deviation value of the T cell subset proportions such that the actual value of the individual's two T cell subset proportions satisfies the theoretical range of the two T cell subset proportions.

[0111] In some embodiments, the theoretical ranges of the proportions of the two T cell subsets are derived from physiological values ​​of a healthy subject population, which is comprised of human individuals aged 5 to 85 years who are not affected by immunodeficiency syndrome or immunohypersensitivity syndrome.

[0112] In some embodiments, when the first T cell subset is CD4 positive T cells (CD4+ T cells) and the second T cell subset is CD8 positive T cells (CD8+ T cells), the theoretical range of the ratio of the two T cell subsets (theoretical range of CD4 / CD8 ratio) is 1:1 to 5:1. It is understood that when the actual value of the CD4 / CD8 ratio is lower than 1:1, the individual will exhibit a state of reduced immunity, since CD4 positive T cells can activate early killer T cells. A pharmaceutical composition containing CD4 positive T cells is administered to the individual, and a suitable dosage of the CD4 positive T cells to be administered is generated according to the individual's blood content, the actual value of the number of CD4 positive T cells (content of CD4 positive T cells in blood) and the corresponding theoretical range.

[0113] In some embodiments, the treatment further comprises administering immune cell therapy to the individual after administering to the individual a pharmaceutical composition comprising the T cells or a pharmaceutical composition comprising the natural killer cells to the individual. In some embodiments, the immune cell therapy comprises natural killer cell therapy, cytokine-induced killer cells therapy, γδ T cell therapy, dendritic cell therapy, tumor infiltrating lymphocytes (TIL) therapy, chimeric antigen receptor T cell therapy, or a combination thereof.

[0114] In addition, none of the conventional immune cell therapies includes a process of comparing the deviation of the actual values ​​of immune analysis indicators, such as the total number of T cells, the total number of natural killer cells, the percentage of T cell subsets, the percentage of natural killer cell subsets, and the CD4 / CD8 ratio, with the corresponding theoretical range in advance, and also includes a process of adjusting the actual values ​​of the immune analysis indicators to the theoretical range based on the deviation of the immune analysis indicators by in vitro culturing lymphocytes, such as T cells, natural killer cells, a specific T cell subset, or a specific natural killer cell subset, and then returning them to an individual, or by removing lymphocytes, such as T cells, natural killer cells, a specific T cell subset, or a specific natural killer cell subset, in the individual. For this reason, the efficacy of existing immune cell therapies varies greatly depending on the differences in the efficacy of the immune system of each individual (e.g., immunosuppression or autoimmune disease).

[0115] In contrast, the use of the present disclosure can ensure that immune cell therapy is performed after an individual's immune efficacy has returned to a good state, thereby increasing the success rate of immune cell therapy.

[0116] For example, before performing T cell-related γδ T cell therapy, dendritic cell therapy, tumor infiltrating lymphocyte therapy or chimeric antigen receptor T cell therapy, the actual total number of T cells can be adjusted to the theoretical range of the total number of T cells and the actual value of the T cell subset proportion can be adjusted to the theoretical range of the T cell subset proportion based on the deviation value of the total number of T cells and the deviation value of the T cell subset, thereby restoring the immune efficacy of T cells to a healthy state and improving the therapeutic effect of immune cells.

[0117] In another embodiment, before performing natural killer cell-related natural killer cell therapy or cytokine-induced killer cell immunotherapy, the actual total number of natural killer cells can be adjusted to the theoretical range of the total number of natural killer cells and the actual value of the proportion of natural killer cell subsets can be adjusted to the theoretical range of the proportion of natural killer cell subsets based on the deviation value of the total number of natural killer cells and the deviation value of the natural killer cell subsets, so that the natural killer cells can restore immune efficacy to a healthy state and enhance the therapeutic effect of immune cells.

[0118] In some embodiments, the lymphocytes are derived from an individual who needs treatment and obtained by in vitro culture. For example, before an individual receives treatment, the lymphocytes are screened from the individual's own blood in advance and cryopreserved, so that in the future, when cancer is treated, they can be directly thawed, screened, expanded and cultured, and then returned to the individual. By preserving the specific lymphocytes in advance, not only can the flow of lymphocytes required for treatment be reduced, but also the immune rejection situation between different individuals can be avoided.

[0119] In some embodiments, the cancer comprises colorectal cancer, ovarian cancer, prostate cancer, breast cancer, brain cancer, cervical cancer, bladder cancer, anal cancer, uterine cancer, colon cancer, liver cancer, pancreatic cancer, lung cancer, endometrial cancer, bone cancer, testicular cancer, skin cancer, kidney cancer, stomach cancer, esophageal cancer, head and neck cancer, salivary gland cancer, hepatocellular carcinoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, basal cell carcinoma, squamous cell carcinoma of the skin, bile duct carcinoma, Merkel cell carcinoma, or a combination thereof.

[0120] The present disclosure further provides a use of a plurality of natural killer cells for preparing a pharmaceutical composition for treating cancer in an individual, the treatment comprising: (a) measuring an actual value of the natural killer cell killing ability of the natural killer cells, the actual value of the natural killer cell killing ability being generated by co-culturing the natural killer cells with a plurality of cancer cells in a specific ratio, and generating a percentage of the death number of the cancer cells to obtain an actual value of the natural killer cell killing ability; (b) generating a deviation value of the natural killer cell killing ability between the actual value of the natural killer cell killing ability and the theoretical range of the natural killer cell killing ability based on the deviation value of the natural killer cell killing ability and the theoretical range of the natural killer cell killing ability; and (c) administering a pharmaceutical composition comprising the natural killer cells to the individual, such that the actual value of the individual's natural killer cell killing ability satisfies the theoretical range of the natural killer cell killing ability based on the deviation value of the natural killer cell killing ability.

[0121] It is known that when an individual is a cancer patient, the killing ability of natural killer cells may be reduced in efficacy or autoimmune hyperactivity due to insufficient or excessive actual total number of natural killer cells or insufficient activity of natural killer cells. The present disclosure controls the actual value of the killing ability of natural killer cells to a theoretical range (e.g., by controlling the actual total number of natural killer cells to a theoretical range or activating natural killer cells in an individual), thereby adjusting the efficacy of the individual's immune system to a healthy state and enhancing the ability of the individual's autoimmune system to resist cancer, thereby improving the therapeutic effect against cancer. Compared with conventional radiation therapy or chemical therapy, the use of the present disclosure does not damage autoimmune cells. It is to be noted that the use of the present disclosure may be combined with other immune cell therapies, and the effect of immune cell therapy is improved by precisely controlling the killing ability of natural killer cells.

[0122] In some embodiments, the theoretical range of killing capacity of natural killer cells is derived from physiological values ​​in a healthy subject population, which is a human individual aged 5 to 85 years who is not affected by immunodeficiency syndrome or immunohypersensitivity syndrome.

[0123] In some embodiments, when the number ratio is 6.25, the theoretical range of the killing ability of natural killer cells is 0% to 58.8%, when the number ratio is 12.5, the theoretical range of the killing ability of natural killer cells is 1.7% to 88.7%, when the number ratio is 25, the theoretical range of the killing ability of natural killer cells is 17.4% to 100%, and when the number ratio is 50, the theoretical range of the killing ability of natural killer cells is 35.3% to 100%.

[0124] In some embodiments, in step (a), when leukocyte interleukin 2 (IL-2) having a number ratio of 50 and an effective concentration of 100 International Units (IU) / milliliter is added simultaneously to co-culture with natural killer cells and cancer cells (referred to as the maximum activity group of natural killer cells or the IL-2 control group), the theoretical range of the killing ability of natural killer cells is 57.4%-100%. Note that, at this effective concentration, IL-2 completely inhibits the activity of regulatory natural killer cells (regulatory natural killer cells inhibit the activity of killer natural killer cells), so the actual value of the killing ability of natural killer cells obtained under this condition reflects the activity of an individual's killer natural killer cells, i.e., the maximum activity of natural killer cells.

[0125] In some embodiments, the treatment includes the steps of generating a natural killer cell total number deviation value between the actual total number of natural killer cells and the theoretical range of the total number of natural killer cells, and administering to the individual a pharmaceutical composition comprising natural killer cells based on the deviation value of the killing ability of natural killer cells and the deviation value of the total number of natural killer cells, so that the actual total number of the individual's natural killer cells satisfies the theoretical range of the killing ability of natural killer cells.

[0126] In some embodiments, the treatment further comprises the steps of: classifying the natural killer cells into a plurality of natural killer cell subsets according to the presence or absence of expression of a plurality of specific antigens, the natural killer cell subsets including regulatory natural killer cells, the regulatory natural killer cells being CD34+, CD56+, CD94+, and CD117+; generating a deviation value of regulatory natural killer cells between an actual percentage of regulatory natural killer cells and a theoretical range of regulatory natural killer cells, the actual percentage of regulatory natural killer cells being a percentage of the number of regulatory natural killer cells in lymphocytes; and administering to the individual a pharmaceutical composition comprising the regulatory natural killer cells based on the deviation value of the killing ability of natural killer cells and the deviation value of regulatory natural killer cells, such that the actual percentage of the individual's regulatory natural killer cells meets the theoretical range of killing ability of regulatory natural killer cells, so that the actual value of the killing ability of the individual's natural killer cells meets the theoretical range of the killing ability of natural killer cells.

[0127] Furthermore, by analyzing the trends of natural killer cell killing ability at different numerical ratios and combining them when the numerical ratio is 50, it is possible to combine this with the natural killer cell killing ability measured when IL-2 is added (maximum activity of natural killer cells) to provide an overview of the immune efficacy of natural killer cells.

[0128] For example, if the proportion of natural killer cells co-cultured with cancer cells is high, but the actual killing power of the natural killer cells in each group is lower than the theoretical range, and the actual killing power of the natural killer cells in the maximum activity group of natural killer cells (IL-2 control group) is also lower than the theoretical range, there will be a deviation in the killing power of the natural killer cells between the actual killing power of the natural killer cells and the theoretical range of the killing power of the natural killer cells.

[0129] Then, the actual total number of natural killer cells can be further analyzed, and if the actual total number of natural killer cells is lower than the corresponding theoretical range, natural killer cells can be administered to the individual so that the actual total number of natural killer cells meets the theoretical range of the total number of natural killer cells, and the actual value of the individual's natural killer cell killing ability meets the theoretical range of the natural killer cell killing ability. On the other hand, the actual percentage of regulatory natural killer cells can also be analyzed at the same time, and if the actual percentage of regulatory natural killer cells is higher than the corresponding theoretical range, it indicates that the efficacy of natural killer cells is excessively inhibited, and the regulatory natural killer cells with an excessively high proportion can be removed so that the actual percentage of regulatory natural killer cells meets the corresponding theoretical range, and the actual value of the natural killer cell killing ability returns to the theoretical range of the natural killer cell killing ability.

[0130] In another embodiment, if the proportion of natural killer cells is high and the actual value of the killing ability of natural killer cells in each group is lower than the theoretical range, but the actual value of the killing ability of natural killer cells in the most active group of natural killer cells (IL-2 control group) is within the theoretical range, this indicates insufficient activity of natural killer cells. Natural killer cells are first selected from an individual, and then subjected to activation culture with IL-2. After confirming that the actual value of the killing ability of natural killer cells of the activated natural killer cells has returned to the corresponding theoretical range, they can be returned to the individual to improve immune efficacy.

[0131] In some embodiments, the treatment further comprises administering to the individual immune cell therapy after administering to the individual a pharmaceutical composition comprising the natural killer cells, in some embodiments, the immune cell therapy comprises natural killer cell therapy, cytokine-induced killer cell immunotherapy, γδ T cell therapy, dendritic cell therapy, tumor infiltrating lymphocyte therapy, chimeric antigen receptor T cell therapy, or a combination thereof.

[0132] In addition, the efficacy of existing immune cell therapies varies greatly depending on the individual's immune system (e.g., immunosuppression or autoimmune disease), whereas the use of the present disclosure can ensure that immune cell therapy is performed after the killing ability of the individual's natural killer cells has returned to a good state, thereby increasing the success rate of immune cell therapy.

[0133] For example, before performing natural killer cell therapy, the actual total number of natural killer cells can be adjusted to the theoretical range of the total number of natural killer cells based on the actual value of the killing ability of natural killer cells and based on the deviation value of the total number of natural killer cells, the deviation value of regulatory natural killer cells, or both, and the actual value of the proportion of natural killer cell subsets can be adjusted to the theoretical range of the proportion of natural killer cell subsets, or both can be performed simultaneously, so that the actual value of the killing ability of natural killer cells falls within the theoretical range of the killing ability of natural killer cells.

[0134] In some embodiments, natural killer cells are derived from an individual who needs treatment and obtained by in vitro culture. For example, before an individual receives treatment, specific lymphocytes are screened from the individual's own blood and cryopreserved, so that in the future, when cancer is treated, they can be directly thawed, screened, expanded and cultured, and then returned to the individual, which not only reduces the flow of natural killer cells required for treatment, but also avoids the immune rejection situation between different individuals.

[0135] In some embodiments, the cancer comprises colorectal cancer, ovarian cancer, prostate cancer, breast cancer, brain cancer, cervical cancer, bladder cancer, anal cancer, uterine cancer, colon cancer, liver cancer, pancreatic cancer, lung cancer, endometrial cancer, bone cancer, testicular cancer, skin cancer, kidney cancer, stomach cancer, esophageal cancer, head and neck cancer, salivary gland cancer, hepatocellular carcinoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, basal cell carcinoma, squamous cell carcinoma of the skin, bile duct carcinoma, Merkel cell carcinoma, or a combination thereof.

[0136] To further illustrate the method and system for detecting the effectiveness of immunity and the use of lymphocytes to prepare a pharmaceutical composition for treating cancer in an individual according to various embodiments of the present disclosure (method for treating cancer by controlling lymphocyte content), the following examples are provided for illustrative purposes only and are not intended to limit the present invention.

[0137] 1. Method and system for detecting the effectiveness of immunity

[0138] 1. Detection of immune cell types and antigen expression status (detection of actual values ​​of immune analysis indicators of T cells and natural killer cells)

[0139] First, 100 microliters of whole blood sample from a human is placed into a test tube containing an appropriate concentration of anticoagulant, which can be heparin or ethylenediaminetetraacetic acid (abbreviation EDTA), and when EDTA is added, the weight percentage of EDTA action is 0.1%.

[0140] Based on the antigens (classification markers) shown in Table 1, select specific antibodies having a fluorescent group (e.g., Fluorescein Isothiocyanate; FITC) and perform immunostaining in combination with an appropriate method depending on the antigen distribution location (e.g., cell surface antigen or intracellular antigen) to label specific cells and classify the cells into multiple cell subsets.

[0141] [Table 1]

[0142] If the selected antigen is a cell surface antigen (e.g., CD3, CD4, CD8, CD25, CD27, CD34, CD39, CD45RO, CD45RA, CD56, CD57, CD62L, CD94, CD117, and CD127), perform the following surface antigen staining steps.

[0143] Add 100 microliters of fluorescently labeled antibody (e.g., Invitrogen's Flow Cytometry Antibodies) into a test tube containing 100 microliters of whole blood sample, so that the volume ratio of whole blood sample to antibody is 1:1, and the antibody dilution ratio is 50 to 100 times. Then, act for 30 minutes to 1 hour at a temperature of 2°C to 8°C with light-shielding rotation. Next, use a flow cytometer staining solution (Invitrogen eBioscience Flow Cytometry Staining Buffer, product number 00-4222-26) to wash the cells in the whole blood sample to obtain the first cell staining solution.

[0144] If the selected antigens include surface antigens and intracellular antigens (e.g., FoxP3), the above surface antigen staining step is performed, followed by the following steps.

[0145] Add 2 milliliters of fixative / lyse solution (Invitrogen eBioscience 1-Step Fix / Lyse Solution (10X), product number 00-5333-54) at room temperature to 100 microliters of the first cell staining solution, and mix by inversion to lyse red blood cells so that they do not interfere with the subsequent flow cytometry analysis. Then, incubate in the dark at room temperature for 15 to 60 minutes to obtain the processing solution.

[0146] The treatment solution was centrifuged at 500 xg for 5 minutes at room temperature to pellet the cells, and the supernatant was removed.

[0147] Under dark conditions, suspend the cells in 2 milliliters of permeabilization solution (prepared by diluting 10 times from Invitrogen eBioscience Permeabilization Buffer (10X) (product number 00-8333-56)). Next, centrifuge at room temperature for 5 minutes at 500 x g, remove the supernatant, and repeat the process of adding permeabilization solution and removing the supernatant by centrifugation.

[0148] Suspend the cells in 100 microliters of flow cytometer staining solution, and add 100 microliters of an antibody labeled with a fluorescent group (e.g., Invitrogen Flow Cytometry Antibodies) to make the antibody dilution ratio 50 to 100 times. Then, act at room temperature, in the dark, for 20 to 60 minutes. Wash the cells using another 2 milliliters of flow cytometer staining solution, remove the supernatant by centrifugation, and then suspend the cells in 500 microliters of flow cytometer staining solution to obtain a second cell staining solution.

[0149] Using a flow cytometer, the antigen data of the sample cell surface is obtained according to the presence or absence of expression of cell classification markers (see Table 1), and the T cell subsets and natural killer cell subsets are classified, and the contents of T cells and natural killer cells in the whole blood sample (the actual total number of T cells and the actual total number of natural killer cells), the proportions of T cell subsets and each natural killer cell subset in lymphocytes (the actual percentages of T cell subsets and the actual percentages of natural killer cell subsets), and the proportions of CD4 positive T cells / CD8 positive T cells are generated. In addition, the proportion of T cells bearing a specific marker antigen (e.g., CD28) in all T cells is analyzed as necessary.

[0150] In addition, the classification markers used in the present application are multi-checked using dedicated antigens for each T cell subset and each natural killer cell subset to further improve the accuracy of classification.

[0151] in particular,

[0152] Regarding early helper T cells, we verified them by adopting dual markers of CD45RA (a marker for early T cells) and CD28 (a marker for early helper T cells) for helper T cells, and also excluded regulatory helper T cells through CD62L (a marker for non-regulatory helper T cells in T cells), thereby reducing the probability of regulatory helper T cells being mixed in.

[0153] Regarding aging helper T cells, we verified this by using CD45RO (a marker for aging T cells) on helper T cells, and also reduced the probability of regulatory helper T cells being mixed in via CD62L.

[0154] Regarding regulatory helper T cells, the accuracy of the classification of regulatory helper T cells can be improved by using the triple antigens CD25, FoxP3, and CD39 specific to regulatory helper T cells for verification.

[0155] Regarding early killer T cells, the early cell marker CD45RA was used to classify early T cells from killer T cells (CD8), and the dedicated marker CD127 for early killer T cells was also used for double verification, which can improve the classification accuracy of early killer T cells.

[0156] Regarding aging killer T cells, the aging cell marker CD45RO was used to classify aging T cells from killer T cells (CD8), and the dedicated marker CD57 for aging killer T cells was also used to perform double verification, thereby improving the accuracy of classification of aging killer T cells.

[0157] For killer natural killer cells and regulatory natural killer cells, both are separated by CD16 (a marker for killer natural killer cells), and both are multiplex-validated via the natural killer cell-specific markers CD34, CD56, CD94, and CD117.

[0158] 2. Detection of the actual killing capacity of natural killer cells

[0159] Because natural killer cells are the first line of defense against viruses and cancer, detecting the killing ability of natural killer cells can be used to evaluate the innate immune ability to resist viruses and cancer, and the detection of the killing ability of natural killer cells includes the following steps:

[0160] First, natural killer cells (e.g., obtained by selecting an appropriate antibody according to Table 1 above and isolating them from a whole blood sample) and K-562 cells are co-cultured at different ratios (effector cell / target cell=ET ratio, e.g., natural killer cells / K-562=6.25, 12.5, 25, 50), and the rate at which K-562 cells die is analyzed using a flow cytometer to evaluate the killing ability of the natural killer cells and determine the health and anti-cancer ability of the natural killer cells.

[0161] In addition, because regulatory natural killer cells inhibit the activity of killer natural killer cells, IL-2 (effective concentration: 100 International Units / milliliter = 100 IU / milliliter) is further added under the condition that the E:T ratio is 50 to inhibit the activity of regulatory natural killer cells, and by comparing with a group to which IL-2 is not added, the killer natural killer cell activity is evaluated, the maximum activity of natural killer cells is analyzed, and it is possible to determine whether the natural killer cells are in a state of immune inhibition.

[0162] Specifically, when the ET ratio increases from 6.25 to 50 in a linear progression, the percentage of the deaths of K-562 cells (or the deaths of K-562 cells) increases in an arithmetic progression, indicating that natural killer cells are healthy and vigorous, and have the ability to eliminate and protect cancer cells. Conversely, when the ET ratio continues to increase, but the percentage of the deaths of K-562 cells (or the deaths of K-562 cells) is lower than the reference range and does not show an arithmetic progression upward trend, it indicates that natural killer cells (especially killer natural killer cells) are not healthy and lack the ability to kill and prevent cancer.

[0163] To further clarify the status of natural killer cells, the percentage of death of K-562 cells in the IL-2 control group and the number of regulatory natural killer cells can be simultaneously referenced.

[0164] In the IL-2 control group, the percentage of K-562 cell death was lower than the reference range, and a high proportion of regulatory natural killer cells indicates an autoimmune state (common causes include cancer and chronic viral infections), whereas a normal proportion of regulatory natural killer cells indicates an immune-compromised state (common causes include aging (especially over 65 years old), drug effects (including, for example, immunosuppressants or chemotherapy), radiation therapy or excessive radiation damage).

[0165] In addition, when the death percentage of K-562 cells in the IL-2 control group fell within the reference range, it indicated that natural killer cells were stimulated and activated to produce anti-cancer toxin, which means that although the primitive activity of natural killer cells was lower than that of normal people, it did not affect the body's health.

[0166] Therefore, by testing the killing ability of natural killer cells, the anti-cancer killing ability and health of natural killer cells can be effectively and quantitatively evaluated, providing a more accurate analysis for clinical disease diagnosis.

[0167] 3. Effectiveness of Analysis Immunity

[0168] The types of immune cells (T cell subsets and natural killer cell subsets) and antigen expression status in the whole blood sample are obtained by the above 1, the actual percentages of each cell subset (T cell subsets and natural killer cell subsets) in lymphocytes are calculated, and the actual values ​​of the killing ability of natural killer cells are obtained by the above 1 and 2, and then the effectiveness of immunity is judged according to the following Tables 2 to 4. If all the actual values ​​are within the reference range (e.g., within the theoretical range or the acceptable range), the effectiveness of immunity is judged to be normal. Furthermore, if the actual values ​​(e.g., actual percentages) of each cell subset meet the theoretical range, the effectiveness of immunity is judged to be good. However, if any of the actual values ​​(e.g., actual percentages) do not meet the reference range (i.e., the theoretical range and the acceptable range), the effectiveness of immunity is judged to be low.

[0169] [Table 2]

[0170] [Table 3]

[0171] [Table 4]

[0172] Moreover, the method for analyzing the effectiveness of immunity can also be implemented in a specific system 300. See Figure 3. The system 300 includes a memory 310, a processor 320, and an output module 330.

[0173] First, using an electronic device such as a personal computer, smartphone, or server, the antigen data on the surface of the sample cells (in the case of antigen expression of cells in a whole blood sample) obtained by flow cytometer analysis in 1 above, "Detection of immune cell type and antigen expression state", is transmitted as a file, and the killing ability data of natural killer cells obtained by 2 above, "Detection of killing ability of natural killer cells", is transmitted to and stored in memory 310 (e.g., read-only memory, flash memory, disk, or cloud database).

[0174] System 300 further includes a processor 320 connected to memory 310, where processor 320 may include a central processor, image processor, microprocessor, etc., including a processing unit including a multi-core or a combination of multiple processing units, and processor 320 accesses the sample cell surface antigen data and natural killer cell killing activity data in memory 310 to perform the following analyses:

[0175] First, the processor 320 analyzes the antigen data on the sample cell surface based on the cell subset database 312 (including the classification information of T cell subsets and the classification information of natural killer cell subsets in Table 1), classifies the cells in the whole blood sample into multiple cell subsets (including multiple T cell subsets and multiple natural killer cell subsets), calculates the percentage of the number of each cell subset among the lymphocyte cells, and obtains data on the number of T cell subsets and data on the number of natural killer cell subsets.

[0176] Next, the processor 320 analyzes the data on the number of T cell subsets, the data on the number of natural killer cell subsets, and the natural killer cell killing ability data based on the immune effectiveness evaluation database 314 (including the reference range data of T cell subsets, the reference range data of natural killer cell subsets, and the reference range data of natural killer cell killing ability in Tables 2 to 4) and generates immune effectiveness data.

[0177] The system 300 further includes an output module 330 coupled to the processor 320, which outputs the immunopotency efficacy data as an immunopotency efficacy report for display on a display screen (not shown) or transmission to another electronic device for evaluating whether to cryopreserve specific T cell subsets or specific natural killer cell subsets.

[0178] 2. Isolation and cryopreservation of target cells

[0179] Based on the results of the analyses 1 and 3 above, it is determined whether a specific T cell subset or a specific natural killer cell subset is to be cryopreserved. For example, if the actual percentage of early helper T cells meets the reference range for early helper T cells, the early helper T cells are cryopreserved.

[0180] 1. Target Cell Isolation

[0181] Target cells (specific T cell subsets or specific natural killer cell subsets) are isolated by immuno-bead cell sorting, which includes a positive sorting system and a negative sorting system.

[0182] A positive selection system (Dynal from Invitrogen) was used. (R) positive i Solation kits and FlowComp TM The selection flow uses antibodies with specially modified biotin (FlowComp TM The process involves marking target cells with the Antibody Mix in the kit series products, and then using streptavidin-containing positive selection magnetic beads (FlowComp TM FlowComp in kit series products TM Dynabeads TM ) to bind the streptavidin and biotin on the positive selection magnetic beads; selecting cells that bind to the positive selection magnetic beads by magnetic force, removing the positive selection magnetic beads that bind to the cells, and obtaining the target cells.

[0183] Negative isolation (Untouched) TM The selection flow uses a mixture of multiple antibodies with biotin (Negative isolation (Untouched) kits). TM The process involves marking the cells to be removed using the antibody mix in the Negative Isolation (Untouched) Kit, and negative isolation (Untouched) Magnetic Beads containing Streptavidin. TM )kits Depletion MyOne TM SA Dynabeads (R) ) is added to bind the streptavidin and biotin on the negative selection magnetic beads, and the cells to be removed are sieved out using magnetic force to select target cells that are not bound to the negative selection magnetic beads.

[0184] Below, examples of methods for selecting each T cell subset and natural killer cell subset are given.

[0185] (1) Regulatory helper T cells (CD3+CD4+CD25+FoxP3+CD39+)

[0186] CD3+CD4+ is used to screen helper T cells (including early helper T cells, senescent helper T cells and regulatory helper T cells), and CD25+CD45- is used to screen regulatory helper T cells.

[0187] The selection process of CD3+ cells is specifically as follows (taking the positive selection system as an example):

[0188] First, peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples, and the PBMCs were cultured at a cell density of 5x10 using a separation solution. 6 The PBMC separation solution was prepared at 100 cells / ml, and the separation solution was a calcium ion- and magnesium ion-free phosphate buffer (purchased from Gibco, product number 14190) supplemented with 0.1% bovine serum albumin (BSA) and 2 mM ethylenediaminetetraacetic acid (EDTA).

[0189] Next, Invitrogen's Dynabeads (R) FlowComp TM Hum An CD3 kit (product number 113-65D) is used to isolate cells expressing CD3, which specifically includes the following steps:

[0190] Mix 25 microliters of a specially modified biotin-containing CD3 antibody (Antibody Mix in the kit) with 500 microliters of PBMC separation solution, and let it react at 2°C to 8°C for 10 minutes to allow the CD3 antibody to bind to the cells expressing CD3. Then wash the PBMC with 2 milliliters of separation solution, centrifuge at 350xg for 8 minutes, and remove the supernatant.

[0191] Next, PBMCs were suspended in 1 milliliter of isolation solution and then 75 microliters of positive selection magnetic beads (FlowComp® in the kit) were added. TM Dynabeads TM ) and rotate at room temperature (about 25°C) for 15 minutes to obtain a positive mixture.

[0192] Next, place the positive mixture on a magnet for at least one minute and remove the supernatant, leaving behind the magnetic bead-labeled cells. After separating the magnetic bead-labeled cells from the magnet, add 1 milliliter of separation solution to suspend the magnetic bead-labeled cells. Place the magnetic bead-labeled cells on a magnet for at least one minute and remove the supernatant.

[0193] Next, add 1 milliliter of magnetic bead removal solution (FlowComp TM Add the release buffer and rotate at room temperature for 10 minutes. Place the magnetic bead-labeled cells in the magnetic bead removal solution on a magnet for 1 minute, then transfer the supernatant (cells expressing CD3) to a new centrifuge tube and centrifuge at 350xg for 8 minutes to pellet the cells. Remove the supernatant to obtain the cells expressing CD3.

[0194] Next, the corresponding set is selected, and by a process similar to that described above, CD4+ cells (CD3+CD4+ cells) are further selected from CD3+ cells, followed by further selecting CD25+ cells (CD3+CD4+CD25+ cells) from the CD3+CD4+ cells, and then selecting and removing CD45+ cells from the CD3+CD4+CD25+ cells to obtain CD45- cells (CD3+CD4+CD25+CD45- cells), thereby obtaining regulatory helper T cells.

[0195] (2) Early helper T cells (CD3+CD4+ CD45RA+CD62L+CD28+) or aged helper T cells (CD3+CD4+CD45RO+CD62L+CD28-)

[0196] Referring to the specific selection process of CD3+ cells mentioned above, the helper T cells (including early helper T cells, aged helper T cells and regulatory helper T cells) are screened with CD3+CD4+, the early helper T cells and aged helper T cells are screened with CD25-CD45+ (here, CD45+ means at least the cells expressing CD45RA or CD45RO, where CD45RA and CD45RO are different isomers of CD45), and finally, the early helper T cells (CD28+) or aged helper T cells (CD28-) are screened with CD28+ or CD28-.

[0197] (3) Early killer T cells or senescent killer T cells

[0198] Referring to the specific selection process of CD3+ cells mentioned above, the killer T cells (including early killer T cells and senescent killer T cells) are screened with CD3+CD8+, and the early killer T cells (CD57-) or senescent killer T cells (CD57+) are screened with CD57- or CD57+.

[0199] (4) Killer natural killer cells or regulatory natural killer cells

[0200] Referring to the specific selection process of CD3+ cells above, the natural killer cell subset (including killer natural killer cells and regulatory natural killer cells) is screened with CD34+CD56+, and the killer natural killer cells (CD16+) or regulatory natural killer cells (CD16-) are screened with CD16+ or CD16-.

[0201] (5) Simultaneous isolation of T cell and natural killer cell subsets from a single blood sample

[0202] The classification markers selected in the present application can sequentially separate each T cell subset and natural killer cell subset from the same blood sample, eliminating the need to separate multiple blood samples to screen each cell subset, saving screening time and consumables, not only increasing screening efficiency but also reducing quantification errors. In addition, the selection of the markers of the present invention allows blood samples to be screened for two antigens at once, and the number of separations can be controlled within the cell tolerance range (2-3 sorting steps) to avoid damaging the cells.

[0203] Therefore, the markers selected in the present application can improve the applicability and accuracy of clinical detection, see the following flow chart for details.

[0204] For T cells

[0205] (1) Helper T cells:

[0206] First, CD3 and CD4 are used to separate T helper cells (CD3 is a T cell marker, and CD4 is a T helper cell marker). For the screened cells, CD45RA (early T cell marker) and CD62L (a marker for non-regulatory T helper cells in T cells), CD45RO (senescent T cell marker) and CD62L, CD25 and FoxP3 (both are regulatory T helper cell markers) are used to primarily separate T helper cells, senescent T helper cells, and regulatory T helper cells. Finally, for the screened cells expressing CD45RA and CD62L or CD25 and FoxP3, CD28 (early T helper cell marker) and CD39 (regulatory T helper cell marker) are used to verify the T helper cells and regulatory T helper cells again, thereby obtaining T helper cells, senescent T helper cells, and regulatory T helper cells.

[0207] (2) Killer T cells:

[0208] After screening the helper T cells, the remaining cells are then screened using CD8 and CD27 (both of which are killer T cell markers) to separate the killer T cells, and CD45RA (early T cell marker) and CD62L (a marker for non-regulatory helper T cells in T cells), CD45RO (senescent T cell marker) and CD62L are respectively used to initially separate the early killer T cells and senescent killer T cells, respectively, and finally, CD127 (early killer T cell marker) and CD57 (senescent killer T cell marker) are respectively used to perform re-examination of the early killer T cells and senescent killer T cells, respectively, to obtain the early killer T cells and senescent killer T cells.

[0209] For natural killer cells,

[0210] After isolating the T cell subset, the unseparated cells are further screened for CD16 (killer natural killer cell marker) and CD34 (natural killer cell marker) to initially isolate killer natural killer cells, and then the killer T cells are screened for multiple times with CD56, CD94, and CD117 (all three of which are natural killer cell markers) to obtain killer natural killer cells.Then, the remaining cells are screened for regulatory T cells with CD34, CD56, CD94, and CD117 in sequence.

[0211] 2. Cryopreservation of Target Cells

[0212] The target cells selected in the above 4.1 "Isolation of target cells" are subcultured, and the culture medium containing the target cells (select the corresponding culture medium according to the different cells) is centrifuged to precipitate the cells, and the supernatant is removed. The target cells are then suspended in a culture medium containing 5% dimethyl sulfoxide (DMSO) by weight to adjust the target cell density to 1x10 6 / ml~5x10 6After making the final volume per milliliter, divide into freezer tubes and store them successively at 4°C for 10 to 30 minutes, at -20°C for 30 minutes, at -80°C for 16 to 18 hours, and finally transfer to liquid nitrogen for long-term frozen storage, or place in a programmed temperature-reducing machine (for example, reduce the temperature by 1 to 3°C per minute) to reduce the temperature to -80°C, and then place in liquid nitrogen for long-term frozen storage.

[0213] If the cells are stored at -20°C for more than an hour, the ice crystals will be too large and the cell viability will decrease. Alternatively, the previous 4°C and -20°C steps can be skipped and the cells can be stored directly at -80°C, however, this will decrease the cell viability.

[0214] Since each T cell subset and natural killer cell subset has a different function and plays a different role in the immune system (for example, early helper T cells are useful for resisting new pathogens, while killer natural killer cells can inhibit cancer), the method and system for detecting the effectiveness of immunity according to the present disclosure classifies T cell subsets (for example, classifying early helper T cells expressing CD28) with a first antigen including CD28, classifies natural killer cell subsets (for example, classifying killer natural killer cells expressing CD16) with a second antigen including CD16, calculates the actual percentage in lymphocyte cells, and analyzes the effectiveness of immunity, thereby providing a more comprehensive test of the functions of each aspect of the immune system.

[0215] 3. Method for Treating Cancer by Regulating Lymphocyte Content

[0216] 1.Detecting the actual value of each immune analysis indicator

[0217] The above method 1 is used to detect the actual values ​​of the immune analysis indicators of T cells and natural killer cells, and the above methods 1 and 2 are used to detect the actual value of the killing ability of natural killer cells.

[0218] 2. Adjust the actual values ​​of individual immune analysis indicators to the theoretical range

[0219] 2.1. Adjusting the actual values ​​of T cell immune analysis indicators to the theoretical range

[0220] According to Table 2 above, generate deviation values ​​between the actual values ​​of each immune analysis index obtained by 3 and 1 above and the corresponding theoretical range, and then generate appropriate dosages at which T cells or specific T cell subsets should be replenished to or removed from the individual based on the individual's blood volume or other relevant immune analysis index actual values.

[0221] Specifically, the following example will be taken as an individual cancer patient weighing 65 kg, with a total blood volume estimated to be 5 liters.

[0222] If we determine that the actual total number of T cells is 500 cells / microliter (theoretical range of total number of T cells is 700 cells / microliter to 2500 cells / microliter), the appropriate dose range for T cell replacement is 1x10 9 ~1x10 10 pieces [(700-500) pieces / microliter) x 5 liters = 1 x 10 9 , (2500-500) pieces / microliter) x 5 liters = 1 x 10 10 By adjusting the actual total number of T cells to the theoretical range, it is possible to improve the immunity of the individual, and further increase the safety and efficacy of the immune cell therapy that is subsequently combined.

[0223] When the number of CD4 positive T cells is detected to be 200 / microliter and the number of CD8 positive T cells is detected to be 250 / microliter, the actual value of the CD4 / CD8 ratio is 0.8:1 (the theoretical range of the CD4 / CD8 ratio is 1:1-5:1). Since CD4 positive T cells can activate early killer T cells, if the ratio of CD4 positive T cells is too low, the individual will be in a state of weakened immunity, and when directly receiving immune cell therapy (such as dendritic cell therapy or chimeric antigen receptor T cell therapy), the anti-cancer effect will be low. In order to improve the immune efficacy, first, positive screening of the CD4 positive T cells in the individual is performed, and then the CD4 positive T cells in the individual are further expanded and cultured, and 2.5x10 8Pieces [(250-200) pieces / microliter x 5 liters = 2.5 x 10 8 ) and at least restore the actual CD4 / CD8 ratio to 1:1. Adjusting the actual CD4 / CD8 ratio to the theoretical range will improve the number of CD4 positive T cells, activate early killer T cells, and improve the individual's anti-cancer killing ability.

[0224] If the actual percentage of early helper T cells is found to be 25% (theoretical range for early helper T cells is ≥ 35% and theoretical range for total number of T cells is 700 cells / microliter to 2500 cells / microliter), the individual will exhibit a state of immunosuppression. To improve the efficacy of immunity, 3.5x10 early helper T cells isolated and obtained from the individual will be 8 pieces~1.25x10 9 Pieces [(35-25)% x 5 liters x 700 pieces / microliter = 3.5 x 10 8 , (35-25)% x 5 liters x 2500 particles / microliter = 1.25 x 10 9 ] and then return it to the individual to restore the actual percentage of initial helper T cells to at least 35% or more. Adjusting the actual percentage of initial helper T cells to a theoretical range can restart the individual's immune anti-cancer mechanism, improve the individual's anti-cancer killing ability, and further increase the success rate when combined with other immune cell therapies.

[0225] Detecting an actual percentage of regulatory helper T cells of 15% (theoretical range of regulatory helper T cells is 3%-10%) and an actual total number of T cells of 2000 cells / microliter indicates an excess of regulatory helper T cells to inhibit other lymphocytes, inhibiting the immune anti-cancer efficacy of the individual. 8 Regulatory helper T cells [(15-10)% x 5 liters x 2000 cells / microliter = 5 x 10 8To improve the condition of excessively inhibited immune function, peripheral blood mononuclear cells (PBMCs) must be extracted from the individual through hemapheresis, and then at least 3.33 x 10 PBMCs must be extracted through lymphopheresis. 9 pieces (5x10 8 CD4-positive T cells (15% / 100 cells) are positively selected, and then CD25-positive regulatory helper T cells are removed by negative selection, after which the remaining PBMCs are returned to the individual.

[0226] Conversely, if you find that the actual percentage of regulatory helper T cells is 2% (theoretical range for regulatory helper T cells is 3%-10%) and the actual total number of T cells is 2000 / microliter, this indicates that there are too few regulatory helper T cells to inhibit other lymphocytes, potentially resulting in a state of autoimmunity. 8 pieces~8x10 8 Regulatory helper T cells were determined by the individual [(3-2)% x 5 liters x 2000 cells / microliter = 1 x 10 8 , (10-2)% x 5 liters x 2000 particles / microliter = 8 x 10 8 ] should be supplemented, which will improve the autoimmune state and reduce the dependency on immunosuppressants. Specifically, PBMCs are first extracted from individuals through a blood separator, and then positively selected regulatory helper T cells are selected through lymphocyte separation. Then, 1x10 regulatory helper T cells are added to the blood. 8 pieces~8x10 8 After amplifying and culturing the cells until they reach the number of individuals, they are returned to the individual.

[0227] If the actual percentage of early killer T cells is found to be 15% (theoretical range for early killer T cells is >20%) and the actual total number of T cells is 2000 cells / microliter, indicating a lack of efficacy of the immune system in killing cancer cells, early killer T cells should be isolated from the individual and at least 5x10 8Number of early killer T cells [(20-15)% x 5 liters x 2000 cells / microliter = 5 x 10 8 The individual cells need to be amplified and cultured, and then returned to the individual, which can restart the individual's immune anti-cancer mechanism, improve the individual's anti-cancer ability, and further increase the success rate when combined with other immune cell therapies.

[0228] 2.2. Adjusting the actual values ​​of natural killer cell immune assay indicators to the theoretical range

[0229] According to Table 3 above, generate deviation values ​​between the actual values ​​of each immune analysis indicator obtained by 3 and 1 above and the corresponding theoretical ranges, and then generate appropriate dosages of natural killer cells or natural killer cell subsets to be replenished or removed according to the individual's blood volume.

[0230] First, the actual value of the killing ability of natural killer cells obtained by the above 3.1 is compared with the theoretical range in the above Table 4 to determine the proportion of each number and the tendency of the actual value of the killing ability of natural killer cells when IL-2 is added and the deviation value from the theoretical range. If the actual value of the killing ability of natural killer cells is not within the theoretical range, the deviation value between the actual value of each immune analysis index related to natural killer cells obtained by the above 3.1 and the theoretical range corresponding to the above Table 3 is generated, and then an appropriate dosage of natural killer cells or a specific natural killer cell subset to be replenished or removed according to the blood volume of the individual is generated, so that the killing ability of natural killer cells can be adjusted to an optimal condition, and the success rate of subsequent combination with other immune cell therapies can be increased.

[0231] Theoretically, when the E:T ratio rises from a ratio such as 6.25 to 50, the number of cancer cells killed by natural killer cells increases in an arithmetic progression, indicating that the natural killer cells of an individual can normally kill cancer cells. In addition, natural killer cells can be stimulated via IL-2 to produce maximum activity, and compared with the control group with an E:T ratio of 50, thereby determining whether the individual is in a state of immunosuppression.

[0232] Specifically, taking an example of an individual who is a cancer patient weighing 65 kg and whose total blood volume is estimated to be 5 liters, the following three possible situations are provided for illustration:

[0233] 1. The E:T ratio is increased, but the actual value of the killing ability of natural killer cells in the E:T ratio of group 4 is lower than the theoretical range, and does not show a trend of increasing linearly. At the same time, the actual value of the killing ability of natural killer cells in the maximum activity group of natural killer cells (IL-2 control group) is lower than the theoretical range, and further, by comparing the actual percentage of regulatory natural killer cells obtained by 3.1 above with the theoretical range corresponding to Table 3, the actual percentage of regulatory natural killer cells is high.

[0234] It is shown that regulatory natural killer cells are usually excessive and excessively inhibit the ability of killer natural killer cells to kill cancer cells. In this case, regulatory natural killer cells with an excessively high percentage are removed according to the actual percentage of regulatory natural killer cells and the corresponding theoretical range in Table 3.

[0235] For example, if the actual percentage of regulated natural killers is 15% (theoretical range for regulated natural killers is ≦10%) and the actual total number of natural killer cells is 5×10 8 When the number of regulatory natural killer cells is 2.5x10, it indicates an excess of regulatory natural killer cells. 7 pieces (5x10 8 It is necessary to remove regulatory natural killer cells (NKCs), which account for 5% of all cells in the blood. Specifically, PBMCs are first extracted from the individual using a blood separator, and then NKCs with CD56 positivity and CD3 negativity are positively selected using lymphocyte separation. The number of cells is 1.67 x 10 8 pieces (2.5x10 7 / 0.15=1.67x10 8), and then further negative selection is used to remove CD16 negative regulatory natural killer cells, after which the remaining natural killer cells (which are primarily killer natural killer cells) are returned to the individual.

[0236] 2. As mentioned above, the E:T ratio is increased in the same way, but the actual value of the killing ability of natural killer cells in the E:T ratio of group 4 is lower than the theoretical range, and does not show a tendency of increasing linearly. At the same time, the actual value of the killing ability of natural killer cells in the maximum activity group of natural killer cells (IL-2 control group) is lower than the theoretical range, and further, by comparing the actual percentage of regulatory natural killer cells obtained by 3.1 above with the theoretical range corresponding to Table 3, if the actual percentage of regulatory natural killer cells is within the theoretical range,

[0237] This usually indicates that the individual is in a severely immunocompromised state, and the common causes are (1) aging (especially in human individuals over 65 years old), (2) drug effects (e.g., immunosuppressants or chemical treatment), and (3) radiation therapy or excessive radiation damage. Usually, such individuals have a situation where the actual total number of natural killer cells is too low, and natural killer cells can be expanded and cultured and then returned to the individual to increase the actual total number of natural killer cells and improve the individual's immunity. In some other embodiments, when comparing the actual percentage of regulatory natural killer cells obtained by 3.1 above with the corresponding theoretical range in Table 3, the actual total number of natural killer cells can be compared with the corresponding theoretical range at the same time, and before carrying out the natural killer cell return process, it is confirmed whether the actual total number of natural killer cells falls within the theoretical range.

[0238] For example, if the actual total number of natural killer cells after detection is 80 cells / microliter (the theoretical range of the total number of natural killer cells is 100 cells / microliter), it indicates that the killing ability of natural killer cells is insufficient, and in order to improve the individual's killing ability against cancer cells, the actual total number of natural killer cells should be increased to at least 1x10 8 Pieces [(100-80) pieces / microliter x 5 liters = 1 x 108 They need to be amplified and cultured in individual cells, and then returned to the individual.

[0239] 3. Similarly, if the E:T ratio increases, but the actual values ​​of the killing ability of natural killer cells in the E:T ratios of the four groups are lower than the theoretical range and do not show an equal increase trend, and at the same time, the actual value of the killing ability of natural killer cells in the maximum activity group of natural killer cells (IL-2 control group) falls within the theoretical range,

[0240] This indicates that the activity of natural killer cells in an individual is lower than that of normal people, but they can be stimulated and activated to improve their ability to kill cancer cells. For this purpose, natural killer cells are first selected from an individual, and then subjected to IL-2 activation culture to confirm that the actual value of the killing ability of the natural killer cells has returned to the theoretical range, after which they can be returned to the individual.

[0241] Therefore, by analyzing the actual value of the killing ability of natural killer cells, the actual total number of natural killer cells, and the actual percentage of regulatory natural killer cells and the corresponding theoretical range, a more comprehensive analysis of the state of the anti-cancer killing ability of natural killer cells can be provided. Furthermore, based on the analysis results, the content of natural killer cells or regulatory natural killer cells in an individual can be correspondingly adjusted, or natural killer cells activated by IL-2 can be added, so that the killing ability of natural killer cells can be restored to the theoretical range, and the success rate of subsequent combination with other immune cell therapies (e.g., natural killer cell therapy) can be improved.

[0242] Although the embodiments have been disclosed as above, they are not intended to limit the disclosure, and anyone skilled in the art may make various changes or modifications without departing from the spirit and scope of the disclosure. Therefore, the scope of protection of the disclosure is determined by the contents specified in the following claims. [Explanation of symbols]

[0243] 100 ways 200 Flow S110, S120, S130, S140, S210, S220, S230 process 300 Systems 310 Memory 312 Cell Subset Database 314 Immune System Effectiveness Evaluation Database 320 Processor 330 Output Module

Claims

1. A system for detecting efficacy of immunity, comprising a processor and a memory, A plurality of computer program instructions are stored in the memory, the computer program instructions, when executed by the processor, causing the processor to: accessing in vitro sample data comprising cell surface antigen data for a plurality of samples of the individual; generating data on the number of a plurality of T cell subsets and data on the number of a plurality of natural killer cell subsets based on the in vitro sample data using a cell subset database including classification information on T cell subsets and classification information on natural killer cell subsets, the classification information on the T cell subsets including a classification index depending on the presence or absence of expression of a plurality of first antigens including CD28, and the classification information on the natural killer cell subsets including a classification index depending on the presence or absence of expression of a plurality of second antigens including CD16; A step of generating efficacy data of immunity based on the number data of the T cell subsets and the number data of the natural killer cell subsets by using an immunity efficacy evaluation database including reference range data of a plurality of T cell subsets and reference range data of a plurality of natural killer cell subsets; A system for detecting the effectiveness of immunity, comprising:

2. 2. The system of claim 1, wherein the first antigen further comprises CD3, CD4, CD8, CD25, CD27, CD39, CD45RO, CD45RA, CD57, CD62L, CD127, FoxP3, or a combination thereof, and the second antigen further comprises CD34, CD56, CD94, CD117, or a combination thereof.

3. 2. The system of claim 1, further comprising an output module coupled to the processor for receiving the immunity validation data and outputting it as an immunity validation report.

4. 4. The system of claim 3, wherein the immunity validation report includes an immunity validation field and a plurality of immunity analysis indicator fields.

5. 2. Use of a plurality of lymphocytes in the preparation of a pharmaceutical composition for treating cancer in an individual, comprising: the lymphocytes include a plurality of T cells, a plurality of natural killer cells, or a combination thereof; The treatment comprises: (a) generating a deviation value of the total number of T cells between the actual total number of T cells and a theoretical range of the total number of T cells, and generating a deviation value of the total number of natural killer cells between the actual total number of natural killer cells and a theoretical range of the total number of natural killer cells; (b) administering to the individual the pharmaceutical composition comprising the T cells based on the T cell total number deviation value such that the actual total number of the T cells in the individual satisfies the T cell total number theoretical range; administering the pharmaceutical composition comprising the natural killer cells to the individual so that the actual total number of the natural killer cells of the individual satisfies the theoretical range of the total number of the natural killer cells based on the deviation value of the total number of the natural killer cells; The use comprising:

6. The use according to claim 5, wherein the theoretical range of the total number of the T cells is 700 cells / microliter to 2500 cells / microliter, and the theoretical range of the total number of the natural killer cells is 100 cells / microliter to 300 cells / microliter.

7. The treatment comprises: (a) classifying the lymphocyte cells into a plurality of T cell subsets depending on the presence or absence of expression of a plurality of first antigens, and classifying the lymphocyte cells into a plurality of natural killer cell subsets depending on the presence or absence of expression of a plurality of second antigens; (b) generating deviations of T cell subsets between actual percentages of T cell subsets and theoretical ranges of T cell subsets, and generating deviations of natural killer cell subsets between actual percentages of natural killer cell subsets and theoretical ranges of natural killer cell subsets, the actual percentages of T cell subsets being the percentage of the number of each of the T cell subsets in the lymphocytes, and the actual percentages of natural killer cell subsets being the percentage of the number of each of the natural killer cell subsets in the lymphocytes; and (c) administering to the individual the pharmaceutical composition comprising the T cell subset based on the deviation value of the T cell subset such that the actual percentage of the T cell subset in the individual fulfills the theoretical range of the T cell subset; administering to the individual the pharmaceutical composition comprising the natural killer cell subset, such that an actual percentage of the natural killer cell subset in the individual satisfies a theoretical range for the natural killer cell subset based on the deviation value of the natural killer cell subset. The use of claim 5 further comprising:

8. the T cell subset comprises early helper T cells, regulatory helper T cells, early killer T cells, or a combination thereof; the early helper T cells are CD3+, CD4+, CD45RA+, CD62L+, and CD28+; the regulatory helper T cells are CD3+, CD4+, CD25+, FoxP3+, and CD39+; The use according to claim 7, characterized in that the primary killer T cells are CD8+, CD27+, CD45RA+, CD62L+, and CD127+.

9. The use according to claim 8, wherein the theoretical range of T cell subsets comprises a theoretical range of early helper T cells, a theoretical range of regulatory helper T cells, a theoretical range of early killer T cells or a combination thereof, wherein the theoretical range of early helper T cells is 35% to 100%, the theoretical range of regulatory helper T cells is 3% to 10%, and the theoretical range of early killer T cells is 20% to 100%.

10. The use according to claim 7, characterized in that the natural killer cell subset comprises regulatory natural killer cells, the regulatory natural killer cells being CD34+, CD56+, CD94+, and CD117+.

11. The use according to claim 10, characterized in that the theoretical range of natural killer cell subsets includes a theoretical range of regulatory natural killer cells which is between 0% and 10%.

12. The treatment comprises: (a) classifying the lymphocytes into a plurality of T cell subsets according to the presence or absence of expression of a plurality of first antigens, the T cell subsets including a first T cell subset and a second T cell subset; (b) generating a deviation value of the T cell subset percentage between the actual value of the two T cell subset percentages and the theoretical range of the two T cell subset percentages, the actual value of the two T cell subset percentages being a ratio of numbers between the first T cell subset and the second T cell subset; and (c) administering the pharmaceutical composition comprising the first T cell subset or the second T cell subset to the individual so that the actual values ​​of the proportions of the two T cell subsets of the individual satisfy the theoretical ranges of the proportions of the two T cell subsets based on the deviation values ​​of the proportions of the T cell subsets. The use according to claim 5, further comprising:

13. The use according to claim 12, characterized in that when the first T cell subset is CD4 positive T cells and the second T cell subset is CD8 positive T cells, the theoretical range of the ratio of the two T cell subsets is 1:1 to 5:

1.

14. The use according to claim 5, characterized in that the treatment further comprises a step of performing immune cell therapy on the individual after the step of administering to the individual the pharmaceutical composition comprising the T cells or the pharmaceutical composition comprising the natural killer cells.

15. The use according to claim 14, characterized in that the immune cell therapy comprises natural killer cell therapy, cytokine-induced killer cell immunotherapy, γδ T cell therapy, dendritic cell therapy, tumor infiltrating lymphocyte therapy, chimeric antigen receptor T cell therapy or a combination thereof.

16. The use according to claim 5, characterized in that said lymphocytes are derived from said individual and are obtained by in vitro culture.

17. The use according to claim 5, characterized in that the cancer comprises colorectal cancer, ovarian cancer, prostate cancer, breast cancer, brain cancer, cervical cancer, bladder cancer, anal cancer, uterine cancer, colon cancer, liver cancer, pancreatic cancer, lung cancer, endometrial cancer, bone cancer, testicular cancer, skin cancer, kidney cancer, gastric cancer, esophageal cancer, head and neck cancer, salivary gland cancer, hepatocellular carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, basal cell carcinoma, cutaneous squamous cell carcinoma, bile duct cancer, Merkel cell carcinoma, or a combination thereof.

18. 1. Use of a plurality of natural killer cells for the preparation of a pharmaceutical composition for treating cancer in an individual, comprising: The treatment comprises: (a) measuring the actual value of the killing ability of the natural killer cells by co-culturing the natural killer cells with a number of cancer cells in a certain ratio, generating a percentage of the deaths of the cancer cells, and obtaining an actual value of the killing ability of the natural killer cells; (b) generating a deviation value of the killing ability of the natural killer cells between the actual value of the killing ability of the natural killer cells and the theoretical range of the killing ability of the natural killer cells based on the actual value of the killing ability of the natural killer cells and the theoretical range of the killing ability of the natural killer cells; and (c) administering the pharmaceutical composition comprising the natural killer cells to the individual so that the actual value of the killing ability of the natural killer cells of the individual satisfies the theoretical range of the killing ability of the natural killer cells based on the deviation value of the killing ability of the natural killer cells. The use comprising:

19. The use according to claim 18, characterized in that, when the number ratio is 6.25, the theoretical range of the killing ability of the natural killer cells is 0% to 58.8%, when the number ratio is 12.5, the theoretical range of the killing ability of the natural killer cells is 1.7% to 88.7%, when the number ratio is 25, the theoretical range of the killing ability of the natural killer cells is 17.4% to 100%, and when the number ratio is 50, the theoretical range of the killing ability of the natural killer cells is 35.3% to 100%.

20. The use according to claim 19, characterized in that in step (a), when the number ratio is 50 and leukocyte interleukin-2 having an effective concentration of 100 international units / milliliter is added simultaneously to co-culture with the natural killer cells and the cancer cells, the theoretical range of the killing ability of the natural killer cells is 57.4% to 100%.

21. The treatment comprises: generating a deviation value of the total number of natural killer cells between the actual total number of natural killer cells and a theoretical range of the total number of natural killer cells; administering the pharmaceutical composition comprising the natural killer cells to the individual based on the deviation value of the killing ability of the natural killer cells and the deviation value of the total number of the natural killer cells, so that the actual total number of the natural killer cells of the individual satisfies the theoretical range of the total number of the natural killer cells, thereby causing the actual value of the killing ability of the natural killer cells of the individual to satisfy the theoretical range of the killing ability of the natural killer cells; 20. The use of claim 19 further comprising:

22. The treatment comprises: classifying said natural killer cells into a plurality of natural killer cell subsets according to the presence or absence of expression of a plurality of antigens, said natural killer cell subsets including regulatory natural killer cells, said regulatory natural killer cells being CD34+, CD56+, CD94+, and CD117+; generating a deviation value of regulatory natural killer cells between an actual percentage of regulatory natural killer cells and a theoretical range of regulatory natural killer cells, said actual percentage of regulatory natural killer cells being a percentage of the number of regulatory natural killer cells in lymphocytes; A step of administering the pharmaceutical composition comprising the regulatory natural killer cells to the individual based on the deviation value of the killing ability of the natural killer cells and the deviation value of the regulatory natural killer cells, so that the actual percentage of the regulatory natural killer cells of the individual satisfies the theoretical range of the killing ability of the regulatory natural killer cells, thereby causing the actual value of the killing ability of the natural killer cells of the individual to satisfy the theoretical range of the killing ability of the natural killer cells.

20. The use of claim 19 further comprising:

Citation Information

Patent Citations

  • Kit and method for comprehensively evaluating functions of immune cells in human peripheral blood

    CN109254147A

  • Method and apparatus for evaluating immunogenic potential, and program

    JP2010145205A

  • Immune promoting composition

    JP2016069285A

  • Immune strength inspection method and immune strength inspection kit

    JP2017129456A

  • Methods for treating side effects of chimeric antigen receptor (CAR) T-cell therapy

    JP2020516605A